<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        57-249-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DINOBAX 5 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLANZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX INC. (SIGNET SITE)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is DINOBAX and your doctor has prescribed it to help relieve the symptoms that are bothering you. DINOBAX can help to control your symptoms and reduce the risk of relapse.&nbsp;</p><p>Although DINOBAX cannot cure your symptoms, it can help you keep them under control as you continue your treatment.<br />DINOBAX is used to treat symptoms of schizophrenia and related psychotic disorders as well as those of bipolar disorder.</p><p>Your doctor may have prescribed DINOBAX for another reason. Ask your doctor if you have any questions about why DINOBAX has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take DINOBAX if you have had an allergic reaction to DINOBAX or any of the ingredients listed in the &ldquo;<strong>Nonmedicinal Ingredients</strong>&rdquo; section of this leaflet. Signs of allergic reaction may include a skin rash, itching, shortness of breath or swelling of the face, lips or tongue.</p><p><strong>Before starting DINOBAX and to get the best possible treatment, be sure to tell your doctor if you:</strong></p><ul><li>are pregnant or plan to become pregnant&nbsp;</li><li>are breast feeding or plan on breast feeding&nbsp;</li><li>have had an allergic reaction to any medicine which you have taken previously to treat your current condition&nbsp;</li><li>have diabetes or a family history of diabetes&nbsp;</li><li>have a history of any problems with the way your heart beats or have any heart problems&nbsp;</li><li>have a history of stroke or high blood pressure&nbsp;</li><li>have risk factors for developing blood clots such as: a family history of blood clots, age over 65, smoking, obesity, recent major surgery (such as hip or knee replacement), immobility due to air travel or other reason, or take oral contraceptives (&ldquo;The Pill&rdquo;).&nbsp;</li><li>are a smoker&nbsp;</li><li>have ever had blackouts or seizures&nbsp;</li><li>are taking any other medicines (prescriptions or over-the-counter medicines)&nbsp;</li><li>drink alcoholic beverages or use drugs&nbsp;</li><li>exercise vigorously or work in hot or sunny places&nbsp;</li><li>have a history of liver problems, hepatitis, or yellowing of the eyes and skin (jaundice)&nbsp;</li><li>have prostate problems&nbsp;</li><li>have intestinal congestion (paralytic ileus)&nbsp;</li><li>have raised pressure within the eye (glaucoma)&nbsp;</li></ul><p>It is important for your doctor to have this information before prescribing your treatment and dosage.<br />&nbsp;</p><p><strong>Effects on Newborns</strong><br />In some cases, babies born to a mother taking DINOBAX during pregnancy have experienced symptoms that are severe and require the newborn to be hospitalized. Sometimes, the symptoms may resolve on their own. Be prepared to seek immediate emergency medical attention for your newborn if they have difficulty breathing, are overly sleepy, have muscle stiffness, or floppy muscles (like a rag doll), are shaking, or are having difficulty feeding.</p><p>&nbsp;</p><p><strong>Take special care with DINOBAX</strong><br />Tell all doctors, dentists and pharmacists who are treating you that you are taking DINOBAX.</p><p>Tell your doctor or pharmacist that you are taking DINOBAX before you start taking any new medicines.</p><p>&nbsp;</p><p><strong>A combination of DINOBAX with the following medicines might make you feel drowsy</strong></p><ul><li>medicines taken for anxiety or to help you sleep&nbsp;</li><li>medicines taken for depression&nbsp;</li></ul><p>The effects of alcohol could be made worse while taking DINOBAX. <strong>It is recommended that you DO NOT drink alcohol while taking DINOBAX.</strong></p><p>&nbsp;</p><p><strong>Taking other medicines</strong><br />You should tell your doctor if you are taking fluvoxamine (antidepressant), ketoconazole (antifungal), or ciprofloxacin (antibiotic), as these medicines may lead to higher concentrations of olanzapine in your blood.</p><p>You should also tell your doctor if you are taking carbamazepine as it may lead to lower concentrations of DINOBAX in your blood, making DINOBAX less effective.</p><p>Only take other medicines while you are on DINOBAX if your doctor tells you that you can. DO NOT give DINOBAX to anyone else. Your doctor has prescribed it for you and your condition.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Usual dose</strong><br />The most important thing about taking DINOBAX is to take it the way your doctor has prescribed - the right dose, every day. Your doctor has decided on the best dosage for you based on your individual situation and needs. Your doctor may increase or decrease your dose depending on your response.</p><p>Although DINOBAX cannot cure your condition, it can help relieve your symptoms. If your symptoms improve or disappear, it is probably because your treatment is working. Studies have shown that, after coming off medication, a relapse of symptoms occurs in about 2 out of 3 patients and is more than double that of patients staying on their medication. That is why it is so important to keep taking DINOBAX, even after your symptoms have improved or disappeared. DINOBAX should be taken for as long as you and your doctor believe it is helping you.</p><p>&nbsp;</p><p><strong>Proper Handling Instructions</strong><br />DINOBAX tablets should be swallowed whole with a glass of water. DINOBAX tablets can be taken with or without food.</p><p>&nbsp;</p><p><strong>Overdose</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.</p></td></tr></tbody></table><p>If you take too much, immediately contact your doctor or go to your nearest hospital emergency department. Show the doctor your package of tablets. Do this even if there are no signs of discomfort or poisoning. The most common signs if you have taken too much DINOBAX are drowsiness and slurred speech.</p><p>&nbsp;</p><p><strong>Missed Dose</strong><br />Take your prescribed dose at the same time each day. If you miss a dose of DINOBAX by a few hours, take the dose when you remember. If most of the day has passed, wait until your next scheduled dose and try not to miss any more. Do not take 2 doses at once.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like other medicines, DINOBAX can cause some side effects. These side effects are most likely to be minor and temporary. However, some may be serious and need medical attention. Many of the side effects are dose related, so it is important not to exceed your prescribed dose. The most common side effects of DINOBAX are:</p><ul><li>drowsiness</li><li>weight gain</li><li>dizziness&nbsp;</li><li>constipation</li><li>fluid retention</li><li>increased appetite&nbsp;</li><li>dry mouth</li><li>a feeling of restlessness (akathisia)&nbsp;</li></ul><p>You should also tell your doctor if you notice any symptoms that worry you, even if you think the problems are not connected with the medicine or are not listed here.</p><p>Because some people experience drowsiness, you should avoid driving a car or operating machinery until you know how DINOBAX affects you. Some people may feel dizzy in the early stages of treatment, especially when getting up from a lying or sitting position. This side effect usually passes after taking DINOBAX for a few days.</p><p>After prolonged use in women, medicines of this type can cause milk secretion or changes in the regularity of their monthly period. On rare occasions, after prolonged use in men, medicines of this type have been associated with breast enlargement. As well, abnormal liver function tests have been reported on occasion.</p><p>Your doctor should check your body weight before starting DINOBAX and continue to monitor it for as long as you are being treated.</p><p>Your doctor should take blood tests before starting DINOBAX. They will monitor blood sugar, and the number of infection fighting white blood cells. Your doctor should continue to monitor your blood for as long as you are being treated.</p><p>If you have high levels of prolactin (measured with a blood test) and a condition called hypogonadism you may be at increased risk of breaking a bone due to osteoporosis. This occurs in both men and women.</p><p>Do not be alarmed by this list of possible side effects. You may not experience any of them. If any of these side effects are experienced they are usually mild and temporary.</p><p>The following table is based on data from placebo-controlled clinical trials and from post-marketing data.<br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td rowspan="2" colspan="2"><p><strong>Symptom/Effect</strong></p></td><td colspan="2"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td rowspan="2"><p><strong>Stop taking drug and call your doctor or pharmacist</strong></p></td></tr><tr><td><p><strong>Only if severe</strong></p></td><td><p><strong>In all cases</strong></p></td></tr><tr><td><p><strong>Common</strong></p></td><td><p>New or worsening constipation</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Uncommon</strong></p></td><td><p>Slow heart beat<sup>1</sup></p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4"><p><strong>Rare</strong></p></td><td><p>Liver inflammation [symptoms of fever, yellow skin or eyes, dark urine, weakness, abdominal pain, nausea, vomiting, loss of appetite, itching]<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p dir="RTL">*✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Low white blood cell count</p><p>[symptoms of infection, such as cold, flu-like symptoms, fever, sore throat, as well as weakness or general feeling of unwellness]<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash<sup>2</sup> (see also Allergic Reaction below)</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Seizure [i.e. loss of consciousness with uncontrollable shaking (&ldquo;fit&rdquo;)]<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">*✔</p></td></tr><tr><td rowspan="10"><p><strong>Very Rare</strong></p></td><td><p>Allergic reaction [symptoms include skin rash, hives, swelling, difficulty breathing]<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">*✔</p></td></tr><tr><td><p>Bruise easily, excessive bleeding<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>High fever, muscle rigidity, rapid heartbeat, profuse sweating, irregular pulse<sup>1,2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">*✔</p></td></tr><tr><td><p>Increased thirst &amp; hunger, frequent urination<sup>1,2</sup></p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle twitching or abnormal</p><p>movements of the face or tongue<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>✔*</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Blood clots: swelling, pain and redness in an arm or leg that can be warm to touch. You may develop sudden chest pain, difficulty breathing and heart palpitations<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pancreas inflammation [symptoms of severe abdominal pain, fever, nausea, vomiting]<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p>Long-lasting (greater than 4 hours in duration) and painful erection of the penis<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p>Sudden weakness or numbness in the face, arms, or legs, and speech or vision problems<sup>3</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">*✔</p></td></tr><tr><td><p>Very dark (&ldquo;tea coloured&rdquo;) urine, muscle tenderness and/or aching<sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr></tbody></table><p><sup>1</sup> Identified from the clinical trial database.<br /><sup>2</sup> Identified from adverse events reported after release onto market.<br /><sup>3</sup> Identified from data from 5 placebo-controlled trials in elderly patients with dementia-related psychosis.<br />* If you think you have these side effects, it is important that you seek medical advice from your doctor immediately</p><p>This is not a complete list of side effects. For any unexpected effects while taking DINOBAX, contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Do not store above 30&deg;C. Protect from light and moisture&nbsp;</li><li>All medicines should be kept out of the reach of children.</li><li>DINOBAX should be stored in its original package.</li><li>The expiry date of this medicine is printed on the package label. Do not use the medicine after this date. If your doctor tells you to stop taking DINOBAX or you find that they have passed their expiry date, please return any leftover medicine to your pharmacist.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance is:</strong><br />Olanzapine USP</p><p><strong>DINOBAX tablets contain the following inactive ingredients:&nbsp;</strong><br />Corn starch, Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, Lactose monohydrate, Magnesium stearate, Microcrystalline cellulose, Polyethylene glycol, and Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: 
Tablets – 5 mg or 10 mg

Physical description: 
DINOBAX 5 mg tablet is- White, round, biconvex, film-coated tablets. Engraved “APO” on one side, “OLA” over “5” on the other side.

DINOBAX 10 mg tablet is- White, round, biconvex, film-coated tablets. Engraved “APO” on one side, “OLA” over “10” on the other side.

Contents of the pack
The tablets are available in blister packs of 28 tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Incorporated<br />150 Signet Drive<br />Toronto, Ontario<br />Canada, M9L 1T9<br />Tel: 1-800-268-4623, Fax: 1-800-609-9444<br />www.apotex.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اسم الدواء الخاص بك هو أقراص دينوباكس وقد وصفه طبيبك لك للمساعدة في تخفيف الأعراض التي تزعجك. أقراص دينوباكس يمكن أن تساعد في السيطرة على الأعراض وتقلل من خطر الانتكاس. على الرغم من عدم قدره أقراص دينوباكس على شفاء الأعراض التي تصيبك، ولكنها تساعدك على إبقائها تحت السيطرة كلما واصلت تناول العلاج.</p><p>تستخدم أقراص &nbsp;دينوباكس لعلاج أعراض الفصام والاضطرابات الذهانية ذات الصلة فضلا عن اضراب الفصام الوجداني (ثنائي القطبية).</p><p>قد يصف لك طبيبك أقراص &nbsp;دينوباكس لسبب آخر. اسأل طبيبك اذا كان لديك أي اسئله عن سبب وصفه أقراص &nbsp;دينوباكس لك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أقراص دينوباكس إذا كان لديك رد فعل تحسسي لـ دينوباكس أو أي من المكونات المذكورة في قسم &laquo;المكونات الغير علاجية&raquo; من هذه النشرة. علامات الحساسية قد تشمل الطفح الجلدي، والحكة، وضيق في التنفس أو تورم في الوجه والشفاه أو اللسان.</p><p>&nbsp;</p><p><strong>قبل البدء بتناول أقراص دينوباكس وللحصول على أفضل علاج ممكن، تأكد أن تخبر طبيبك إذا كنت:</strong></p><ul><li>حاملا أو تخططين لتصبحي حاملا</li><li>ترضعين رضاعه طبيعية أو تخططين لذلك.</li><li>كان لديك رد فعل تحسسي من أي دواء كنت قد تناولته سابقا لعلاج حالتك.</li><li>لديك مرض السكري أو تاريخ عائلي لمرض السكري</li><li>لديك تاريخ مسبق لأي مشاكل تتعلق بطريقه دقات قلبك أو لديك أي مشاكل في القلب</li><li>لديك تاريخ من السكتة الدماغية وارتفاع ضغط الدم</li><li>لديك عوامل خطر لتكون جلطات الدم مثل: تاريخ عائلي من جلطات الدم، العمر أكثر من 65 سنة، والتدخين، والسمنة، عملية جراحية كبيرة في الآونة الأخيرة (مثل الورك أو استبدال الركبة)، عدم الحركة بسبب السفر جوا أو لأسباب أخرى، أو تناول وسائل منع الحمل عن طريق الفم (&laquo;حبوب منع الحمل&raquo;)</li><li>مدخنا</li><li>قد أصبت في ما مضى بفقدان الوعي أو نوبات الصرع</li><li>تتناول أي أدوية أخرى (الأدوية التي تصرف بوصفة أو بدون وصفة طبية)</li><li>تتناول المشروبات الكحولية أو تتعاطى المخدرات</li><li>&nbsp;تمارس التمارين الرياضية بقوه أو تعمل في أماكن حارة أو مشمسة</li><li>لديك تاريخ مسبق للإصابة بمشاكل في الكبد، والتهاب الكبد، أو اصفرار في العينين والجلد (اليرقان)</li><li>لديك مشاكل البروستاتا</li><li>لديك انسداد معوي (العلوص الشللي)</li><li>لديك ارتفاع في الضغط داخل العين (الجلوكوما)</li></ul><p>من المهم لطبيبك أن يكون على علم بهذه المعلومات قبل وصف العلاج والجرعات.</p><p>&nbsp;</p><p><strong>الآثار على المواليد الجدد</strong><br />في بعض الحالات، الأطفال الذين يولدون لأم تتناول أقراص دينوباكس أثناء الحمل تتكون لديهم أعراض حادة تتطلب إدخال الأطفال حديثي الولادة إلى المستشفى. في بعض الأحيان، قد تنجلي الأعراض من تلقاء نفسها. كن على استعداد لطلب الرعاية الطبية الطارئة الفورية لحديثي الولادة إذا كان لديهم صعوبة في التنفس، والنعاس المفرط، لديهم تصلب العضلات، أو مرونة العضلات (مثل الدمية الخرقة)، والهز، أو يواجهون صعوبة في الرضاعة.</p><p>&nbsp;</p><p><strong>اتبع عناية خاصة مع أقراص دينوباكس&nbsp;</strong><br />أخبر جميع الأطباء وأطباء الأسنان والصيادلة الذين يعالجونك انك تتناول أقراص دينوباكس.&nbsp;</p><p>أخبر طبيبك أو الصيدلي انك تتناول أقراص دينوباكس قبل البدء في تناول أي أدوية جديدة.</p><p>&nbsp;</p><p><strong>الجمع بين أقراص دينوباكس و الأدوية التالية قد يجعلك تشعر بالنعاس</strong></p><ul><li>الأدوية التي تؤخذ للقلق أو للمساعدة على النوم</li><li>الأدوية التي تؤخذ لعلاج الاكتئاب</li></ul><p>آثار الكحول يمكن أن تزداد سوءا مع تناول أقراص دينوباكس. فمن المستحسن أن <strong>لا تشرب الكحول</strong> في حين تناول أقراص دينوباكس.</p><p>&nbsp;</p><p><strong>تناول أدوية أخرى</strong><br />يجب عليك إخبار الطبيب إذا كنت تتناول فلوفوكسامين (مضاد للاكتئاب)، الكيتوكونازول (مضاد للفطريات)، أو سيبروفلوكساسين (مضاد حيوي)، حيث أن هذه الأدوية قد تؤدي إلى حدوث تركيزات أعلى من الأولانزابين في دمك.</p><p>يجب عليك أيضا أخبار طبيبك إذا كنت تتناول الكاربامازبين حيث أنه قد يؤدي إلى تركيزات أقل من دينوباكس في الدم، مما يجعل دينوباكس أقل فعالية.</p><p>بإمكانك تناول أدوية أخرى أثناء تناولك لأقراص أبو-أولانزابين الذائبة بالفم فقط إذا سمح لك الطبيب بذلك. لا تعطي أقراص دينوباكس إلى أي شخص آخر. فطبيبك قد وصفه لك أنت ولحالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة المعتادة</strong><br />الشيء الأكثر أهمية حول تناول أقراص دينوباكس هو تناولها بالطريقة التي وصفها الطبيب - الجرعة المناسبة، كل يوم. لقد قرر طبيبك أفضل جرعة لك على أساس حالتك الشخصية واحتياجاتك. قد يزيد أو ينقص طبيبك من جرعتك اعتمادا على استجابتك.</p><p>على الرغم من أن أقراص دينوباكس لا يمكنها شفاء حالتك، ولكنها يمكن أن تساعد في تخفيف الأعراض الخاصة بك. إذا تحسنت الأعراض أو اختفت، فربما يكون ذلك لأن العلاج الخاص بك يؤدي عمله. وقد أظهرت الدراسات أنه بعد تناول الدواء، يحدث تراجع للأعراض في حوالي 2 من أصل 3 مرضى، وأكثر من ضعف هذا في المرضى الذين استمروا على أدويتهم. لهذا السبب نجد أنه من المهم جدا أن تستمر بتناول أقراص دينوباكس حتى بعد أن تكون أعراضك قد تحسنت أو اختفت. ينبغي أن تتناول أقراص دينوباكس طالما أنت وطبيبك تعتقدان انها تساعدك.</p><p><strong>تعليمات طريقه التناول الصحيحة</strong><br />يمكنك أن تتناول دينوباكس مع أو بدون الطعام. قم بابتلاع دينوباكس مع كوب من الماء. تناول فالور في الوقت نفسه تقريبا كل يوم.</p><p>&nbsp;</p><p><strong>الجرعة الزائدة</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>في حالة تناول جرعة زائدة من هذا العقار، اتصل على الفور بالطبيب أو قسم الطوارئ بالمستشفى أو مركز مكافحة السموم الإقليمي لديك، حتى لو لم تظهر أعراض.</p></td></tr></tbody></table><p>&nbsp;</p><p>إذا كنت تتناول أكثر من اللازم، اتصل فورا بطبيبك أو اذهب إلى أقرب قسم طوارئ في المستشفى. أظهر لطبيبك عبوة الأقراص الخاصة بك. عليك القيام بذلك حتى لو لم تكن هناك أي علامات انزعاج أو تسمم. العلامات الأكثر شيوعا إذا كنت قد تناولت الكثير من أقراص دينوباكس هي النعاس وثقل اللسان.</p><p>&nbsp;</p><p><strong>الجرعة المنسية</strong><br />تناول الجرعة الموصوفة في نفس الوقت كل يوم. إذا كنت قد نسيت تناول جرعة من أقراص دينوباكس &nbsp;من قبل بضع ساعات، قم بتناول الجرعة حال تذكرها. إذا كان معظم اليوم قد مر، انتظر حتى الجرعة القادمة المقررة لك وحاول عدم تفويت الجرعة مره أخرى. لا تتناول جرعتين في وقت واحد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية الأخرى، يمكن لأقراص دينوباكس أن تسبب بعض الآثار الجانبية. هذه الآثار الجانبية هي من الأكثر احتمالا أن تكون بسيطة ومؤقتة. ومع ذلك، قد يكون بعضها خطيرة وتحتاج إلى عناية طبية. العديد من الآثار الجانبية ذات صله بالجرعة، ولذلك فمن المهم أن لا تتجاوز الجرعة الموصوفة. الآثار الجانبية الأكثر شيوعا لأقراص دينوباكس هي:</p><ul><li>النعاس</li><li>زيادة الوزن</li><li>الدوخة</li><li>زيادة الشهية</li><li>احتباس السوائل</li><li>الإمساك</li><li>جفاف الفم</li><li>شعور الأرق (تعذر الجلوس)</li></ul><p>يجب عليك أيضا إخبار الطبيب إذا لاحظت أي أعراض تقلقك، حتى لو كنت تعتقد أن المشاكل غير مرتبطة بالدواء أو لم يتم سردها هنا.</p><p>لأن بعض الناس قد أصيب بالنعاس، يجب تجنب قيادة السيارات أو تشغيل الآلات حتى تعرف كيف تؤثر أقراص دينوباكس عليك. بعض الناس قد يشعرون بالدوار في المراحل الأولى من العلاج، وخصوصا عند النهوض بعد الاستلقاء أو الجلوس. هذه الآثار الجانبية عادة ما تزول بعد تناول أقراص دينوباكس لبضعه أيام .&nbsp;</p><p>بعد الاستعمال لفترة طويلة في النساء، يمكن لأدوية من هذا النوع أن تسبب إفراز الحليب أو تغيرات في انتظام الدورة الشهرية الخاصة بهن. في حالات نادرة، و بعد الاستعمال لفترة طويلة في الرجال، نجد أن هذه الأدوية من هذا النوع قد ارتبطت بتضخم الثدي. كذلك، تم الإبلاغ عن حدوث نتائج غير طبيعية لفحوصات وظائف الكبد في بعض الأحيان.</p><p>يجب على طبيبك أن يتحقق من وزن الجسم قبل البدء بتناول أقراص دينوباكس ومواصلة رصد ذلك طالما انت تتناول العلاج.</p><p>يجب على طبيبك إجراء فحوصات الدم قبل البدء بتناول أقراص دينوباكس. وسيقوم طبيبك بمراقبة نسبة السكر في الدم، وعدد خلايا الدم البيضاء في دمك والتي تكافح العدوى. وعلى طبيبك أن يستمر بمتابعة دمك طالما انت تتناول العلاج.</p><p>إذا كان لديك مستويات عالية من هرمون البرولاكتين (تقاس بواسطة اختبار الدم) وتعاني من حاله تسمى حالة قصور الغدد التناسلية قد تكون في خطر متزايد للإصابة بكسر العظام نتيجة لهشاشة العظام. يحدث هذا في كل من الرجال والنساء.</p><p>لا تندهش من هذه القائمة من الآثار الجانبية المحتملة. قد لا تواجه أي واحد منها. وإذا تعرضت لأي من هذه الآثار الجانبية عادة ما تكون خفيفة ومؤقتة.</p><p>ويستند الجدول التالي على بيانات من التجارب الإكلينيكية المقارنة بالعلاج الوهمي ومن بيانات مرحلة ما بعد التسويق.<br />&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>آثار جانبية خطيرة، مدى تكرار حدوثها، وماذا تفعل حيالها</strong></p></td></tr><tr><td rowspan="2" colspan="2"><p dir="RTL"><strong>العرض/الأثر</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي </strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن استخدام الدواء واطلب الرعاية الطبية الطارئة الفورية</strong></p></td></tr><tr><td><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td><p dir="RTL"><strong>نادرة</strong></p></td><td><p dir="RTL">إمساك جديد أو متفاقم</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>غير شائعة</strong></p></td><td><p dir="RTL">دقات قلب بطيئة<sup>1</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td rowspan="4"><p dir="RTL"><strong>نادرة</strong></p></td><td><p dir="RTL">التهاب الكبد [أعراض الحمى، اصفرار الجلد أو العينين، البول الداكن، والضعف، وآلام في البطن، والغثيان، والقيء، وفقدان الشهية، والحكة ]<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL">[أعراض الإصابة بالعدوى، مثل البرد وأعراض تشبه الأنفلونزا، الحمى والتهاب الحلق، وكذلك ضعف أو شعور عام بالمرض ]<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">الطفح<sup>2 </sup>(انظر أيضا رد الفعل التحسسي أدناه)</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">نوبة الصرع [أي فقدان الوعي مع الهز الذي لا يمكن السيطرة عليه (&laquo;تشنج&raquo;)]<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td></tr><tr><td rowspan="10"><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جداً</strong></p><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">رد الفعل التحسسي [الأعراض تشمل الطفح الجلدي، حمى القش، وتورم، وصعوبة في التنفس]</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td></tr><tr><td><p dir="RTL">سهوله حدوث الكدمات والنزيف المفرط<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">ارتفاع في درجة الحرارة، تصلب</p><p dir="RTL">العضلات، سرعة ضربات القلب،</p><p dir="RTL">التعرق الغزير، وعدم انتظام النبض<sup>1، 2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td></tr><tr><td><p dir="RTL">زيادة العطش والجوع، وكثرة التبول<sup>1، 2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">ارتعاش العضلات أو حركات غير طبيعية في الوجه أو اللسان<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">الجلطات الدموية: تورم وألم واحمرارفي الذراع أو الساق التي يمكن أن تكون دافئة عند اللمس. قد تصاب فجأه بألم في الصدر، صعوبة في التنفس وخفقان القلب<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">التهاب البنكرياس [أعراض آلام شديدة في البطن والحمى والغثيان، والتقيؤ]<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL">الانتصاب لفترات طويلة (أكثر من 4 ساعات في المدة) وانتصاب مؤلم في القضيب<sup>2</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL">ضعف مفاجئ أو خدر في الوجه</p><p dir="RTL">والذراعين، أو الساقين، و مشاكل في الكلام أو في الرؤية<sup>3</sup></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔*</p></td></tr><tr><td><p dir="RTL">البول الغامق جدا (&laquo;بلون الشاي&raquo;) البول، ووهن العضلات و / أو الالم</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr></tbody></table><p><sup>1</sup> تم تحديدها من قاعدة بيانات التجارب السريرية.<br /><sup>2</sup> تم تحديدها من الأحداث السلبية وذكرت بعد الطرح في السوق.<br /><sup>3</sup> تم التعرف عليها من نتائج دراسات مقارنة أولانزابين بعلاج وهمي في التجارب السريرية في المرضى المسنين المصابين بذهان المتعلق بالخرف.<br />* إذا كنت تعتقد أن لديك هذه الآثار الجانبية، فمن المهم أن تطلب المشورة الطبية من الطبيب على الفور</p><p>هذه ليست قائمة كاملة من الآثار الجانبية. عند حدوث أي آثار غير متوقعة أثناء تناول أقراص دينوباكس، اتصل بطبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>لا يُحفظ في درجة حرارة أعلى من 30 درجة مئوية.</li><li>يٌحفظ بعيداً عن الضوء و الرطوبة.</li><li>يجب أن تبقى جميع الأدوية بعيدا عن متناول الأطفال.</li><li>يجب أن يتم تخزين أقراص دينوباكس في عبوتها الأصلية.</li><li>يتم طباعة تاريخ انتهاء هذا الدواء على ملصق العبوة. لا تستخدم هذا الدواء بعد هذا التاريخ. إذا طلب طبيبك منك التوقف عن تناول أقراص دينوباكس أو وجدت أن تاريخ الصلاحية قد انتهى، الرجاء اعاده &nbsp;أي دواء متبقي إلى الصيدلي.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة الفعالة:</strong><br />أولانزابين حسب موسوعة الأدوية الأمريكية (USP)</p><p><strong>&nbsp;</strong>سليلوز دقيق البلورات، نشا الذرة، هيدروكسي بروبيل السليلوز، هيدروكسي بروبيل الميثيل سليلوز، مغنيسيوم الإستارات، مونوهيدرات اللاكتوز، البولي&nbsp;ايثيلين جلايكول، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشكل الصيدلاني:</strong><br />&nbsp;أقراص 5 ملجم و 10 ملجم</p><p><strong>الوصف الفيزيائي:</strong><br />تركيز 5 ملجم: أقراص بيضاء، مستديرة، مسطحه الوجه، مغلفة مشطوفة ذي حدين. محفور عليها &laquo;APO&raquo; على جانب واحد، &laquo;OLA&raquo; &nbsp;فوق &laquo;5&raquo; على الجانب الآخر</p><p>تركيز 10 ملجم: أقراص بيضاء، مستديرة، مسطحه الوجه، مغلفة مشطوفة ذي حدين. محفور عليها &laquo;APO&raquo; على جانب واحد، &laquo;OLA&raquo; &nbsp;فوق &laquo;10&raquo; على الجانب الآخر.&nbsp;</p><p><strong>&nbsp;محتويات العلبة</strong><br />الأقراص متوفرة في شرائط معدنية من 28 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name in GCC: Dinobax
Trade Name in Country of Origin: Apo-Olanzapine Generic Name: Olanzapine
Dosage Form: Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                See section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 mg: White, round, biconvex, film-coated tablets. Engraved "APO" on one side, "OLA" over "5" on the other side.
10 mg: White, round, biconvex, film-coated tablets. Engraved "APO" on one side, "OLA" over "10" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults:</strong></p><p><em><strong>Schizophrenia and Related Disorders</strong></em></p><p>APO-OLANZAPINE (olanzapine) is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. In controlled clinical trials, olanzapine was found to improve both positive and negative symptoms.</p><p>Olanzapine has been shown to be effective in maintaining clinical improvement during 1-year of continuation therapy in patients who had shown an initial treatment response.</p><p>&nbsp;</p><p><em><strong>Bipolar Disorder</strong></em></p><p>APO-OLANZAPINE (olanzapine) is indicated for the acute treatment of manic or mixed episodes in bipolar I disorder. Olanzapine may be used as monotherapy or cotherapy with agents commonly used in the treatment of acute bipolar disorder (e.g., lithium or divalproex sodium).</p><p>The efficacy of olanzapine as monotherapy maintenance treatment in bipolar patients with manic or mixed episodes who responded to acute treatment with olanzapine was demonstrated in two 1- year &ldquo;time to relapse&rdquo; trials (see 5.3).</p><p>The physician who elects to use APO-OLANZAPINE for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see 4.2).</p><p><strong>Geriatrics </strong><strong>(&ge; 65 years): &nbsp;APO-OLANZAPINE is not indicated in elderly patients with dementia. </strong>See <strong>4.4 - Serious Warnings and Precautions Box </strong>and <strong>Special Populations. </strong>Caution should be used when treating geriatric patients with APO-OLANZAPINE. See 5.4, 4.4, Special Populations, and 4.2 sections.</p><p><strong>Pediatrics</strong><strong> (&lt; 18 years of age)</strong>: The safety and efficacy of olanzapine have not been established in pediatric populations and its use is not recommended. See also 4.4, Pediatrics (&le; 18 years of age) and 4.8, Other Investigational Trials, Adverse Events in Adolescents Patients (ages 13-17 years).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Oral Administration</strong></p><p><strong><u>Schizophrenia and Related Disorders</u></strong></p><p>Adults:&nbsp; APO-OLANZAPINE (olanzapine) should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 5 mg per day are recommended. An increase to a dose greater than target dose of 10 mg/day (i.e., to a dose of 15 mg/day or greater) is normally recommended only after clinical assessment.</p><p>In clinical trials a dose range of 5-20 mg/day was studied (see 5.3).</p><p>Doses above 20 mg/day have been evaluated from a safety perspective (see Table 4 in 4.8, Dose- Dependent Adverse Events subsection); however, efficacy at doses above 20mg/day has not been systematically evaluated.</p><p>&nbsp;</p><p><em><u>Maintenance Therapy in Schizophrenia:</u></em></p><p>It is recommended that responding patients with schizophrenia be continued on olanzapine at the lowest dose needed to maintain remission. Patients should be reassessed periodically to determine the need for maintenance treatment. While there is no body of evidence available to answer the question of how long the patient should be treated with olanzapine, the effectiveness of maintenance treatment is well established for many other antipsychotic drugs.</p><p>&nbsp;</p><p><strong><u>Bipolar Disorder</u></strong></p><p><em><u>Bipolar Mania</u></em></p><p>Adults:&nbsp; The recommended starting dose for olanzapine is 15 mg administered once a day in monotherapy and 10 mg daily in combination therapy.</p><p>It may be given without regard to meals as its absorption is not affected by food. The dosage range of olanzapine is from 5 mg to 20 mg per day. Daily dosage should be adjusted in response to clinical assessment.</p><p>&nbsp;</p><p><em><u>Maintenance Therapy </u></em><em><u>in Bipolar Disorder</u></em><em>:</em></p><p>Patients who have been receiving and responding to olanzapine for the treatment of acute manic or mixed episodes of bipolar disorder should initially continue maintenance therapy at the same dose (see 5.3). Subsequent daily dosage should be adjusted on the basis of clinical status within a range of 5-20 mg per day.</p><p>Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment.</p><p>&nbsp;</p><p><strong><u>General Considerations for Oral Dosing in Special Populations</u></strong></p><p><em><u>The Elderly or Debilitated Patient:</u></em></p><p>In clinical trials, 44 patients with schizophrenia or related disorders who were 65 years of age or over were treated with olanzapine (5-20 mg daily) (see 4.4, Special Populations). Given the limited experience with olanzapine in the elderly, and the higher incidence of concomitant illness and concomitant medication in this population, olanzapine should be used with caution.</p><p>The recommended starting dose is 5 mg in patients who are elderly, debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine&nbsp; (e.g., nonsmoking female patients), or who may be pharmacodynamically more sensitive to olanzapine. When indicated, dose escalation should be performed with caution in these patients.</p><p>&nbsp;</p><p><em><u>Patients with Hepatic and/or Renal Impairment:</u></em></p><p>As clinical experience is lacking in these patients, the lower initial starting dose and slower titration to initial target dose should be considered. Further dose escalation, when indicated, should be conservative (see 4.4, Special Populations).</p><p>&nbsp;</p><p><strong><u>Missed</u></strong><strong><u> Dose</u></strong></p><p>If a patient misses a dose by a few hours, advise patient to take as soon as he/she remembers. If most of the day has passed, advise patient to wait until the next scheduled dose. Advise patients to not take 2 doses of olanzapine at once.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-OLANZAPINE (olanzapine) is contraindicated in those patients with a known hypersensitivity to the drug or the excipients of the product. For a complete listing, see 2.0.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>SERIOUS WARNINGS AND PRECAUTIONS</strong></p><p><u>Increased</u><u> Mortality in Elderly Patients with Dementia</u>:</p><p>Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of thirteen placebo controlled trials with various atypical antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6 fold increase in death rate in the drug-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. (See 4.4, <u>Special Populations</u>, Use in Geriatric Patients with Dementia)</p></td></tr></tbody></table><p><strong><u>General</u></strong></p><p><u>Neuroleptic Malignant Syndrome:</u></p><p>Neuroleptic malignant syndrome (NMS) is a potentially fatal symptom complex that has been reported in association with antipsychotic drugs, including olanzapine.</p><p>Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</p><p>In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.), and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). &nbsp;Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.</p><p>The management of NMS should include 1) immediate discontinuation of all antipsychotic drugs including olanzapine and other drugs not essential to therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment for uncomplicated NMS.</p><p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential re- introduction of therapy should be very carefully considered. The patient should be carefully monitored since recurrences of NMS has been reported.</p><p>&nbsp;</p><p><u>Weight Gain:</u></p><p>Olanzapine was associated with weight gain during clinical trials. Clinically significant weight gain was observed across all baseline body mass index (BMI) categories (see 4.8, Other Adverse Events Observed During Clinical Trials with Olanzapine Across All Indications, Weight Changes). Using pooled data from patients treated with olanzapine over the dosage range of 5 mg to 20 mg per day mean gain was 5.4 kg. The mean change in weight was comparable for patients with schizophrenia and bipolar mania. A retrospective analysis of 573 patients receiving olanzapine for up to 3 years found that dose was not a significant predictor of greater long-term changes in weight.</p><p>In long-term studies (at least 48 weeks), both the magnitude of weight gain and the proportion of olanzapine-treated patients who had clinically significant weight gain were greater than in short- term studies. The percentage of patients who gained &ge;25% of their baseline body weight with long-term exposure was very common (&ge;10%).</p><p>&nbsp;</p><p><u>Body Temperature Regulation:</u></p><p>Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing olanzapine for patients who will be experiencing conditions which may contribute to an elevation of core temperature, e.g. exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.</p><p><u>Potential Effect on Cognitive and Motor Performance:</u></p><p>Because olanzapine may cause somnolence, patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that olanzapine therapy does not affect them adversely.</p><p>&nbsp;</p><p><strong><u>Carcinogenesis</u></strong><strong><u> and Mutagenesis</u></strong></p><p>For animal data, see 5.4, Toxicology section.</p><p>&nbsp;</p><p><strong><u>Cardiovascular</u></strong></p><p><u>Hypotension and Syncope:</u></p><p>As with other drugs that have high alpha-1 adrenergic receptor blocking activity, olanzapine may induce orthostatic hypotension, tachycardia, dizziness, and sometimes syncope, especially at the initiation of treatment. In a clinical trial database of 2500 patients treated with oral olanzapine, syncope was reported in 0.6% (15/2500). The risk of orthostatic hypotension and syncope may be minimized by initiating therapy with 5 mg QD (see 4.2). A more gradual titration to the target dose should be considered if hypotension occurs.</p><p>Olanzapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).</p><p>&nbsp;</p><p><u>Venous Thromboembolism:</u></p><p>Venous thromboembolism (VTE), including fatal pulmonary embolism, has been reported in temporal association with antipsychotic drugs, including olanzapine, in case reports and/or observational studies. When prescribing olanzapine, all potential risk factors for VTE should be identified and preventative measures undertaken, particularly since patients with schizophrenia often present with risk factors for VTE. Very rare cases of VTE have been reported in olanzapine</p><p>-treated patients during the post-marketing period.</p><p>&nbsp;</p><p><u>QT Interval:</u></p><p>In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] &ge; 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF&lt;500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. However, as with other antipsychotics, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia (see 4.8, Post-Market Adverse Drug Reactions).</p><p>&nbsp;</p><p><u>Cardiac Death:</u></p><p>In a retrospective observational study, patients treated with atypical antipsychotics (including olanzapine) or typical antipsychotics had a similar dose-related increase of presumed sudden cardiac death (SCD) compared to non-users of antipsychotics (almost twice the risk than that for non-users). In postmarketing reports with olanzapine, the event of SCD has been reported very rarely.</p><p>&nbsp;</p><p><strong><u>Endocrine </u></strong><strong><u>and Metabolism</u></strong></p><p><u>Hyperglycaemia:</u></p><p>As with some other antipsychotics, exacerbation of pre-existing diabetes and hyperglycaemia have been reported rarely and diabetic ketoacidosis and diabetic coma including some fatal cases have been reported very rarely during the use of olanzapine , sometimes in patients with no reported history of hyperglycaemia (see 4.8; Post-Market Adverse Drug Reactions section). In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Patients should have baseline and periodic monitoring of blood glucose and body weight.</p><p>In clinical trials (up to 52 weeks) olanzapine was associated with a greater mean change in glucose relative to placebo. Treatment-emergent clinically significant changes in fasting glucose were observed in patients with or without evidence of glucose dysregulation at baseline (see 4.8, Other Adverse Events Observed During Clinical Trials with Oral and Intramuscular Olanzapine Across All Indications, Glucose Changes).</p><p>Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.</p><p>Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><u>Hyperprolactinemia:</u></p><p>As with other drugs that block dopamine D2 and/or serotonin 5-HT2&nbsp;receptors, olanzapine may elevate prolactin levels. Elevations associated with olanzapine treatment are generally mild, and may decline during continued administration.</p><p>Since tissue culture experiments indicate that approximately one third of human breast cancers are prolactin-dependent <em>in</em><em> vitro</em>, olanzapine should only be administered to patients with previously detected breast cancer if the benefits outweigh the potential risks. Caution should also be exercised when considering olanzapine treatment in patients with pituitary tumours. Possible manifestations associated with elevated prolactin levels are amenorrhea, galactorrhea, and menorrhagia.</p><p>As is common with compounds which stimulate prolactin release, the administration of olanzapine resulted in an increase in the incidence of mammary neoplasms in both rats and mice. The physiological differences between rats and humans with regard to prolactin make the clinical significance of these findings unclear. To date, neither clinical nor epidemiological studies have shown an association between chronic administration of these drugs and mammary tumorigenesis.</p><p>Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone mineral density in both female and male subjects.</p><p>&nbsp;</p><p><u>Lipids:</u></p><p>Increases in lipids have been observed in olanzapine-treated patients in placebo-controlled clinical trials.&nbsp; Treatment-emergent clinically significant changes in fasting lipids were observed in patients with or without evidence of dyslipidemia at baseline (see 4.8; Other Adverse Events Observed During Clinical Trials with Olanzapine Across All Indications, Lipids subsection).</p><p>Appropriate clinical monitoring is recommended, including baseline and follow-up lipid evaluations.</p><p>&nbsp;</p><p><strong><u>Gastrointestinal</u></strong></p><p><u>Antiemetic Effect:</u></p><p>Consistent with its dopamine antagonist effects, olanzapine may have an antiemetic effect. Such an effect may mask signs of toxicity due to overdosage of other drugs, or may mask symptoms of disease such as brain tumour or intestinal obstruction.</p><p>&nbsp;</p><p><strong><u>Genitourinary</u></strong></p><p><u>Priapism:</u></p><p>Rare cases of priapism have been reported with antipsychotic use, such as olanzapine. This adverse reaction, as with other psychotropic drugs, did not appear to be dose-dependent and did not correlate with the duration of treatment. The most likely mechanism of action of priapism is a relative decrease in sympathetic tone.</p><p>&nbsp;</p><p><strong><u>Hematologic</u></strong></p><p><u>Hematologic Indices:</u></p><p>In oral olanzapine clinical trials, there were no data to suggest olanzapine adversely affected bone marrow function, even in patients with a history of clozapine-associated neutropenia or leukopenia. Olanzapine was associated with a 5.7% incidence of mainly transient treatment- emergent elevations of eosinophil counts above the normal range. Elevations were not associated with any symptoms, identifiable allergic phenomena, or changes in other hematologic indices.</p><p>Rare cases of leukopenia have been reported with olanzapine. In case of symptoms of infection, WBC count and differential count should be considered.</p><p>Neutropenia, granulocytopenia and agranulocytosis have been reported during antipsychotic use. Therefore, it is recommended that patients have their complete blood count (CBC) tested prior to starting olanzapine and then <u>periodically </u>throughout treatment.</p><p>&nbsp;</p><p><strong><u>Hepatic</u></strong></p><p><u>Aminotransferase Elevations</u>:</p><p>During pre-marketing clinical trials, therapy with oral olanzapine was associated with elevation of hepatic aminotransferases, primarily ALT (SGPT). Within a clinical trial database of 2280 olanzapine-treated patients, with baseline ALT (SGPT) levels &le;60 IU/L, 5.9% (134/2280) had treatment-emergent ALT (SGPT) elevations to &gt;120 IU/L, 1.9% (44/2280) had elevations to&gt;200 IU/L, and 0.2% (5/2280) had elevations to &gt;400 IU/L. No patients had values in excess of 700 IU/L. None of the olanzapine-treated patients who had elevated transaminase values manifested clinical symptomatology associated with liver impairment. The majority of aminotransferase elevations were seen during the first six weeks of treatment. Most elevations were transient (66%) while patients continued on olanzapine therapy, or falling (11%) at the last available measurement. Of the 134 olanzapine-treated patients whose enzyme levels increased to</p><p>&gt;120 IU/L, 20 discontinued treatment (6 for hepatic, 14 for other reasons) while their ALT (SGPT) values were still rising. In 38 olanzapine-treated patients with baseline ALT (SGPT) &gt;90 IU/L, none experienced an elevation to &gt;400 IU/L.</p><p>Rare post-marketing reports of hepatitis have been received. Very rare cases of cholestatic or mixed liver injury have also been reported in the post-marketing period. Hepatic failure, including fatalities has also been reported very rarely in the post-marketing period. See 4.8.</p><p>Precaution should be exercised when using olanzapine in patients with pre-existing hepatic disorders, in patients who are being treated with potentially hepatotoxic drugs, or if treatment- emergent signs or symptoms of hepatic impairment appear.</p><p>For patients who have known or suspected abnormal hepatic function prior to starting olanzapine, standard clinical assessment including measurement of aminotransferase levels is recommended. Periodic clinical reassessment with aminotransferase levels is recommended for such patients, as well as for patients who develop any signs and symptoms suggestive of a new onset liver disorder during olanzapine therapy.</p><p>&nbsp;</p><p><strong><u>Neurologic</u></strong></p><p><u>Tardive Dyskinesia:</u></p><p>Tardive dyskinesia (TD), a syndrome consisting of potentially irreversible involuntary dyskinetic movements, is associated with the use of antipsychotic drugs. Tardive dyskinesia occurs more frequently in elderly patients; however, patients of any age can be affected. It is unknown whether antipsychotic drugs may differ in their potential to cause TD. However, during long- term, double-blind, extension schizophrenia maintenance trials (894 olanzapine-treated patients; median olanzapine treatment, 237 days), olanzapine was associated with a statistically significantly lower incidence of treatment-emergent dyskinesia compared to haloperidol. During long-term, double-blind, monotherapy extension bipolar maintenance trials (567 olanzapine- treated patients, for up to 1 year), there were no cases of TD in the olanzapine arms, as determined by either reported adverse events or the Abnormal Involuntary Movement Scale (AIMS).&nbsp; TD has been reported very rarely (&le;0.0025%) in post-market surveillance.</p><p>The risk of developing tardive dyskinesia and the chance of it becoming irreversible are believed to increase as the duration of treatment and the cumulative dose of antipsychotic drug increase. However, the syndrome can develop, although less commonly, after relatively brief periods of treatment at low doses. There is no known treatment for established cases of TD. The syndrome may remit, partially or completely, if antipsychotic drug treatment is withdrawn. Antipsychotic drug treatment itself, however, may suppress the signs and symptoms of tardive dyskinesia, thereby masking the underlying process.</p><p>Given these considerations, olanzapine should be prescribed in a manner that is most likely to minimize the risk of tardive dyskinesia. As with any antipsychotic drug, olanzapine should be reserved for patients who appear to be receiving substantial benefit from the drug. In such patients the lowest effective dose and the shortest duration of treatment should be sought. The need for continued treatment should be reassessed periodically.</p><p>If signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, drug discontinuation should be considered. However, some patients may benefit from continued treatment with olanzapine despite the presence of the syndrome.</p><p>&nbsp;</p><p><u>Seizures:</u></p><p>Conventional neuroleptics are known to lower seizure threshold. In clinical trials, seizures have occurred in a small number (0.9%, 22/2500) of olanzapine treated patients. There were confounding factors that may have contributed to the occurrence of seizures in many of these cases. Olanzapine should be used cautiously in patients who have a history of seizures or have conditions associated with seizure or have a lowered seizure threshold.</p><p>&nbsp;</p><p><strong><u>Psychiatric</u></strong></p><p><u>Suicide:</u></p><p>The possibility of suicide or attempted suicide is inherent in psychosis, and thus close supervision and appropriate clinical management of high-risk patients should accompany drug therapy.</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p><u>Uric Acid:</u></p><p>In the pre-marketing clinical trial database, oral olanzapine was associated with mild elevations of uric acid in some patients. However, only 1 olanzapine-treated patient experienced treatment- emergent gout, and the baseline uric acid concentration for this patient was at least as large as all concentrations observed while the patient was receiving olanzapine.</p><p>&nbsp;</p><p><strong><u>Special</u></strong><strong><u> Populations</u>&nbsp;</strong></p><p><u>Pregnant Women:</u></p><p>There are no adequate and well-controlled studies in pregnant women. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine. Because human experience in pregnant females is limited, this drug should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>&nbsp;</p><p><u>Non-Teratogenic Effects:</u></p><p>Neonates exposed to antipsychotic drugs (including olanzapine) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p><p>Olanzapine should not be used during pregnancy unless the expected benefits to the mother markedly outweigh the potential risks to the fetus.</p><p>&nbsp;</p><p><u>Labour and Delivery:</u></p><p>Parturition in rats was not affected by olanzapine. The effect of olanzapine on labour and delivery in humans is not known.</p><p>&nbsp;</p><p><strong>Nursing Women:</strong></p><p><u>Lactation:</u></p><p>In a study in lactating, healthy women, olanzapine was excreted in breast milk. Mean infant exposure (mg/kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/kg). Patients should be advised not to breast feed an infant if they are taking olanzapine.</p><p>&nbsp;</p><p><strong>Pediatrics</strong><strong> (&lt; 18 years of age):</strong></p><p>The safety and efficacy of olanzapine in children under the age of 18 years have not been established and its use is not recommended.</p><p>Weight gain has been observed with atypical antipsychotic use in pediatric and adolescent patient populations. Independent of any changes during treatment with atypical antipsychotics, weight gain can be associated with adverse changes in other metabolic parameters (e.g., glucose and lipid metabolism). Abnormal childhood weight and metabolic status have been associated with adverse cardiovascular outcomes in adulthood. Weight gain and changes in other metabolic parameters associated with atypical antipsychotics can be more frequent or more severe in pediatric and adolescent patients than in the adult patients.</p><p>The long-term safety of atypical antipsychotics, including potential cardiometabolic effects and effects on growth, maturation and behavioural development in patients under 18 years of age has not been systematically evaluated.</p><p>A greater magnitude of weight gain and lipid alterations has been reported in adolescents compared with adults. Adolescents treated with olanzapine experienced a significantly higher incidence of elevated prolactin levels and significantly higher mean increases in prolactin levels compared with adults. Hepatic aminotransferase elevations are more common in adolescents as compared to adults. Sedation-related events are more common in adolescents as compared to adults.</p><p>See also 4.8/Other Investigational Trials/Adverse Events in Adolescent Patients (ages 13-17 years).</p><p>&nbsp;</p><p><strong>Geriatrics</strong><strong> (&ge;65 years of age):</strong></p><p>The number of patients 65 years of age or over with schizophrenia or related disorders exposed to oral olanzapine during clinical trials was limited (N=44). Caution should thus be exercised with the use of olanzapine&nbsp; in the elderly patient, recognizing the more frequent hepatic, renal, central nervous system, and cardiovascular dysfunctions, and more frequent use of concomitant medication in this population (see 4.2).</p><p>&nbsp;</p><p><strong>Use in Geriatric Patients with Dementia</strong></p><p><u>Overall Mortality</u>:</p><p>Elderly patients with dementia treated with atypical antipsychotic drugs showed increased mortality compared to placebo in a meta-analysis of 13 controlled trials of various atypical antipsychotic drugs. In five placebo-controlled trials with oral olanzapine in this population, the incidence of mortality was 3.5 % for olanzapine-treated patients compared to 1.5 % for placebo- treated patients. Olanzapine is not indicated in elderly patients with dementia.</p><p>&nbsp;</p><p><u>Dysphagia</u>:</p><p>Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer&rsquo;s disease. Olanzapine and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.</p><p>&nbsp;</p><p><u>Cerebrovascular Adverse Events (CVAEs), Including Stroke, in Elderly Patients with Dementia</u>: Cerebrovascular adverse events (e.g. stroke, transient ischemic attack), including fatalities, were reported in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo- controlled studies, there was a higher incidence of CVAEs in patients treated with olanzapine compared to patients treated with placebo (1.3 % vs. 0.4%, respectively; see 4.8). Olanzapine is not approved for the treatment of elderly patients with dementia.</p><p>&nbsp;</p><p>There is insufficient evidence to determine whether CVAEs in elderly patients with dementia are associated specifically with olanzapine or all antipsychotic agents. Clinical trial data appear to suggest that patients with a dementia diagnosis of vascular or mixed type had a higher likelihood of experiencing CVAEs than other types of dementia.</p><p>The risks and benefits of the use of olanzapine in elderly patients with dementia should be assessed taking into account the risk predictors for CVAEs in the individual patient.</p><p>Patients/caregivers should be advised to immediately report signs and symptoms of potential CVAEs, such as sudden weakness or numbness in the face, arms, or legs, and speech or vision problems.</p><p>&nbsp;</p><p><strong>Use in Patients with Other Concomitant Illness:</strong></p><p>Clinical experience with olanzapine in patients with concomitant illness is limited. Caution is thus advised when using olanzapine in patients with diseases or conditions that could affect the metabolism or the pharmacodynamic activity of olanzapine (see 4.2 and 5.4).</p><p>&nbsp;</p><p><em>Use in Patients with Cardiac Disorders:</em></p><p>Olanzapine has not been evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these conditions were excluded from pre-marketing clinical trials.</p><p>&nbsp;</p><p><em>Use in Patients with Diabetes and Risk Factors for Development of Diabetes:</em></p><p>As with some other antipsychotics, exacerbation of pre-existing diabetes and hyperglycaemia have been reported rarely, and diabetic ketoacidosis and diabetic coma including some fatal cases have been reported very rarely during the use of olanzapine, sometimes in patients with no reported history of hyperglycaemia (see 4.8, Post-Market Adverse Drug Reactions section). In some cases, a prior increase in body weight has been reported which may be a pre-disposing factor. Appropriate clinical monitoring is advisable in diabetic patients and in patients with risk factors for the development of diabetes mellitus.</p><p>&nbsp;</p><p><em>Use in Patients with Renal and Hepatic Impairment:</em></p><p>Small single-dose clinical pharmacology studies (see 5.4) did not reveal any major alterations in olanzapine pharmacokinetics in subjects with renal or hepatic impairment. Given the limited clinical experience with olanzapine in patients with these conditions, caution should be exercised (see 4.2).</p><p>&nbsp;</p><p><em>Other</em><em> Concomitant Illnesses:</em></p><p>As olanzapine demonstrated anticholinergic activity <em>in vitro</em>, caution is advised when prescribing for patients with symptomatic prostatic enlargement, narrow-angle glaucoma or paralytic ileus and related conditions.</p><p>In clinical trials, a single case of pre-existing intracranial hypertension was exacerbated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Drug-Drug</u></strong><strong><u> Interactions</u></strong></p><p><em>Alcohol: </em>Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting drugs and alcohol since additive pharmacological effects such as increased sedation may occur.</p><p><em>Levodopa</em><em> and Dopamine Agonists: </em>As it exhibits <em>in vitro </em>dopamine antagonism, olanzapine may antagonize the effects of levodopa and dopamine agonists.</p><p><em>Antihypertensive Agents: &nbsp;</em>Because of its potential for inducing hypotension, olanzapine may enhance the effects of certain antihypertensive agents. Caution should be exercised in patients who receive medicinal products that can induce hypotension, bradycardia, or respiratory depression.</p><p>&nbsp;</p><p><em><u>Potential</u></em><em><u> for Other Drugs to Affect APO-OLANZAPINE:</u></em></p><p><em>Carbamazepine: </em>Concomitant carbamazepine therapy may induce the metabolism of olanzapine.</p><p><em>Activated Charcoal:&nbsp; </em>The concomitant administration of activated charcoal reduced the oral bioavailability of olanzapine by 50% to 60%.</p><p><em>Antacids: </em>Single doses of antacid (aluminium, magnesium) or cimetidine did not affect the oral bioavailability of olanzapine.</p><p><em>Valproate: </em>Studies <em>in vitro </em>using human liver microsomes showed that olanzapine has little potential to inhibit the glucuronidation of valproate, which is the major metabolic pathway.</p><p>Furthermore, valproate was found to have little effect on the metabolism of olanzapine <em>in vitro</em>. Daily concomitant <em>in vivo </em>administration of 10 mg olanzapine for 2 weeks did not affect steady state plasma concentrations of valproate. Therefore, concomitant olanzapine administration does not require dosage adjustment of valproate.</p><p><em>Fluoxetine: &nbsp;</em>Fluoxetine (60 mg single dose or 60 mg daily for 8 days) causes a mean 16% increase in the maximum concentration of olanzapine and a mean 16% decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.</p><p><em>CYP1A2 Inducers: </em>Agents that induce CYP1A2 such as omeprazole may increase clearance of olanzapine.</p><p><em>CYP1A2 Inhibitors:&nbsp; </em>Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine Cmax following fluvoxamine was 54% in female nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC was 52% and 108%, respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin or ketoconazole. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.</p><p><em><u>Potential</u></em><em><u> for APO-OLANZAPINE to Affect Other Drugs:</u></em></p><p><em>Theophylline: </em>The pharmacokinetics of theophylline, a drug principally metabolized by CYP1A2, were not altered by olanzapine in a clinical trial with single doses of IV theophylline.</p><p><em>Imipramine/Desipramine: &nbsp;</em>In clinical trials with single doses of olanzapine, no inhibition of the metabolism of imipramine/desipramine (P450-CYP2D6) was evident.</p><p><em>Warfarin: &nbsp;</em>In clinical trials with single doses of olanzapine, no inhibition of the metabolism of warfarin (P450 CYP2C9) was evident.</p><p><em>Diazepam: &nbsp;</em>In clinical trials with single doses of olanzapine, no inhibition of the metabolism of diazepam (P450 CYP3A4) was evident.</p><p><em>Lithium or Biperiden: </em>Olanzapine showed no interaction when coadministered with lithium or biperiden.</p><p><em>Drugs Metabolized via P450-CYP1A2, -CYP2C9, -CYP2C19, -CYP2D6, and -CYP3A: </em>In <em>in vitro </em>studies with human microsomes, olanzapine showed little potential to inhibit cytochromes P450- CYP1A2, -CYP2C9, -CYP2C19, -CYP2D6, and -CYP3A (see 5.4). Olanzapine is thus unlikely to cause clinically important drug-drug interactions mediated through the metabolic routes outlined above. However, the possibility that olanzapine may alter the metabolism of other drugs, or that other drugs may alter the metabolism of olanzapine, should be considered when prescribing olanzapine.</p><p>&nbsp;</p><p><strong><u>Drug-Food</u></strong><strong><u> Interactions</u></strong></p><p>Absorption of olanzapine is not affected by food.</p><p>&nbsp;</p><p><strong><u>Drug-Herb</u></strong><strong><u> Interactions</u></strong></p><p>Interactions with herbal products have not been identified.</p><p>&nbsp;</p><p><strong><u>Drug-Laboratory</u></strong><strong><u> Interactions</u></strong></p><p>Interactions with laboratory tests have not been identified.</p><p>&nbsp;</p><p><strong><u>Drug-Lifestyle Interactions</u></strong></p><p><em>Smoking: </em>Concomitant smoking may induce the metabolism of olanzapine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See 4.4, Special Populations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because olanzapine may cause somnolence, patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that olanzapine therapy does not affect them adversely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The stated frequencies of adverse events represent the proportion of individuals who experienced at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that although the events were reported during therapy, they were not necessarily caused by the therapy.</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p>The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The figures cited, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence in the populations studied.</p><p>&nbsp;</p><p><strong><u>Incidence </u></strong><strong><u>of Adverse Events Associated with Discontinuation:</u></strong></p><p>ORAL ADMINISTRATION</p><p><em>Schizophrenia</em><em> and Related Disorders:</em></p><p>In short-term, placebo-controlled trials, there was no statistically significant difference in rates of discontinuation of olanzapine or placebo attributed to adverse events. Overall, 5% of olanzapine- treated patients discontinued treatment for adverse events compared with 6% of placebo-treated patients. Discontinuations due to ALT (SGPT) elevations, however, were considered to be drug related (2% for olanzapine versus 0% for placebo) (see 4.4, Renal subsection).</p><p>&nbsp;</p><p><em>Bipolar Disorder: Bipolar Mania</em></p><p>In short-term, placebo-controlled clinical trials, there was no difference overall in the incidence of discontinuation due to adverse events (2% for olanzapine versus 2% for placebo).</p><p>&nbsp;</p><p><em>Bipolar Maintenance</em></p><p>In the long-term (1-year), placebo-controlled clinical trial, of the 225 olanzapine-treated patients, 16% (n = 35) discontinued due to an adverse event, compared with 9% (n = 12) of 136 placebo- treated patients.</p><p>In the long-term (1-year), active-controlled clinical trial, of the 217 olanzapine-treated patients, 19% (n = 41) discontinued due to an adverse event, compared with 26% (n = 55) of 214 lithium- treated patients.</p><p>&nbsp;</p><p><em>All Short-Term Trials </em>- <em>Schizophrenia</em><em> and Bipolar Mania Trials:</em></p><p>In short-term, active-controlled clinical trials, of the 1796 oral olanzapine-treated patients in comparative clinical trials with haloperidol, 98 (5%) discontinued treatment for adverse events compared with 66 of 810 (8%) haloperidol-treated patients.</p><p>&nbsp;</p><p><em>All Short-Term Trials </em><strong>- </strong><em>Overall</em><em> Integrated Safety Database:</em></p><p>In a pre-marketing clinical trial database of 2500 olanzapine-treated patients, 14.9% (372/2500) discontinued due to an adverse event. About half (183/372) of these discontinuations were associated with the underlying psychopathology. Other adverse events most commonly (incidence of 0.5% - 0.6%) reported as the reason for discontinuation among olanzapine-treated patients were: ALT (SGPT) increased, unintended pregnancy, creatine phosphokinase increased, and convulsion.</p><p>&nbsp;</p><p><u>Incidence of Commonly Observed Adverse Events:</u></p><p>ORAL ADMINISTRATION</p><p><em>Schizophrenia</em><em> and Related Disorders:</em></p><p>In the schizophrenia placebo-controlled trials, the most commonly observed adverse events associated with the use of olanzapine (incidence of &ge; 5% and at least twice placebo) were: dizziness (11% for olanzapine vs 4% for placebo), constipation (9% vs 3%), ALT (SGPT) increased (8% vs 3%), personality disorder (8% vs 4%), weight gain (6% vs 1%), akathisia (5% vs 1%), and postural hypotension (5% vs 2%).</p><p>&nbsp;</p><p><em>Bipolar Disorder: Bipolar Mania</em></p><p>In the bipolar mania monotherapy placebo-controlled trials, the most commonly observed adverse events associated with the use of olanzapine (incidence of &ge;5% and at least twice placebo) were: somnolence (35% vs 13%), dry mouth (22% vs 7%), dizziness (18% vs 6%), asthenia (15% vs 6%), constipation (11% vs 5%), dyspepsia (11% vs 5%), increased appetite (6% vs 3%), and tremor (6% vs 3%).</p><p>In bipolar mania combination placebo-controlled trials, the most commonly observed adverse events associated with the combination of olanzapine and lithium or valproate (incidence of &ge; 5% and at least twice placebo) were: dry mouth (32% for olanzapine combination vs 9% for placebo), weight gain (26% vs 7%), increased appetite (24% vs 8%), dizziness (14% vs 7%), back pain (8% vs 4%), constipation (8% vs 4%), speech disorder (7% vs 1%), increased salivation (6% vs 2%), amnesia (5% vs 2%), and paresthesia (5% vs 2%). In addition to the latter list of adverse events identified during bipolar mania combination clinical trials tremor (&ge; 10%) has also been identified.</p><p>&nbsp;</p><p><em>Bipolar Maintenance</em></p><p>In the one-year &lsquo;time to relapse&rsquo; placebo-controlled clinical trial in bipolar disorder, the most commonly observed adverse events associated with olanzapine (incidence of &ge; 5% and at least twice placebo) were: weight increased (8% for olanzapine vs 1.5% for placebo), headache NOS (6.7% vs 2.9%), fatigue (6.2% vs 1.5%), depression (5.8% vs 2.9%).</p><p>&nbsp;</p><p><em>Other</em><em> Indication Trials:</em></p><p>Abnormal gait and falls have been observed very commonly (&ge;10%) in clinical trials with elderly patients with dementia-related psychosis. Also, urinary incontinence and pneumonia were commonly reported (&ge; 1% and &lt;10%) in these patients.</p><p>In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson&rsquo;s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.</p><p>&nbsp;</p><p><u>Adverse Events Occurring at an Incidence of 1% or More Among Oral Olanzapine-Treated</u> <u>Patients:</u></p><p>Certain portions of the discussion below relating to objective or numeric safety parameters are derived from studies in patients with schizophrenia and have not been duplicated for bipolar disorder trials. However, this information is also generally applicable to bipolar disorder. Table 1 enumerates the incidence of treatment-emergent adverse events, rounded to the nearest percent, that occurred during acute therapy (up to 6 weeks) of schizophrenia in 1% or more of patients treated with oral olanzapine (doses &ge; 2.5 mg/day) where the incidence in patients treated with olanzapine was greater than the incidence in placebo-treated patients.</p><p>&nbsp;</p><p><strong>Table 1: Schizophrenia Trials: Treatment-Emergent Adverse Events Incidence in Placebo-Controlled Clinical Trials with Oral Olanzapine - Acute Phase</strong><sup><strong>1</strong></sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Percentage</strong><strong> </strong><strong>of Patients Reporting Event</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Body System/Adverse Event</strong></p></td><td><p><strong>Olanzapine (N=248)</strong></p></td><td><p><strong>Placebo</strong><strong> </strong><strong>(N=118)</strong></p></td></tr><tr><td colspan="3"><p><strong><em>Body As a Whole</em></strong></p></td></tr><tr><td><p>Headache</p></td><td><p>17%</p></td><td><p>15%</p></td></tr><tr><td><p>Pain</p></td><td><p>10%</p></td><td><p>9%</p></td></tr><tr><td><p>Fever</p></td><td><p>5%</p></td><td><p>3%</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>4%</p></td><td><p>2%</p></td></tr><tr><td><p>Back pain</p></td><td><p>4%</p></td><td><p>3%</p></td></tr><tr><td><p>Chest pain</p></td><td><p>4%</p></td><td><p>2%</p></td></tr><tr><td><p>Neck rigidity</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Intentional injury</p></td><td><p>1%</p></td><td><p>0%</p></td></tr><tr><td colspan="3"><p><strong><em>Cardiovascular</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Postural hypotension</p></td><td><p>5%</p></td><td><p>2%</p></td></tr><tr><td><p>Tachycardia</p></td><td><p>4%</p></td><td><p>1%</p></td></tr><tr><td><p>Hypotension</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td colspan="3"><p><strong><em>Digestive System</em></strong></p></td></tr><tr><td><p>Constipation</p></td><td><p>9%</p></td><td><p>3%</p></td></tr><tr><td><p>Dry mouth</p></td><td><p>7%</p></td><td><p>4%</p></td></tr><tr><td><p>Gamma glutamyl transpeptidase increased</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Increased appetite</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td colspan="3"><p><strong><em>Hemic and Lymphatic</em></strong></p></td></tr><tr><td><p>Leukopenia</p></td><td><p>1%</p></td><td><p>0%</p></td></tr><tr><td colspan="3"><p><strong><em>Metabolic</em></strong><strong><em> and Nutritional Disorders</em></strong></p></td></tr><tr><td><p>SGPT increased</p></td><td><p>8%</p></td><td><p>3%</p></td></tr><tr><td><p>Weight gain<sup>2</sup></p></td><td><p>6%</p></td><td><p>1%</p></td></tr><tr><td><p>Edema</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>Peripheral edema</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>SGOT increased</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>Creatine phosphokinase increased</p></td><td><p>1%</p></td><td><p>0%</p></td></tr><tr><td colspan="3"><p><strong><em>Musculoskeletal</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Arthralgia</p></td><td><p>3%</p></td><td><p>2%</p></td></tr><tr><td><p>Joint disorder</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Twitching</p></td><td><p>2%</p></td><td><p>1%</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Percentage</strong><strong> </strong><strong>of Patients Reporting Event</strong></p></td></tr><tr><td><p>&nbsp;</p><p><strong>Body System/Adverse Event</strong></p></td><td><p><strong>Olanzapine (N=248)</strong></p></td><td><p><strong>Placebo</strong><strong> </strong><strong>(N=118)</strong></p></td></tr><tr><td colspan="3"><p><strong><em>Nervous</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Somnolence<sup>2</sup></p></td><td><p>26%</p></td><td><p>15%</p></td></tr><tr><td><p>Agitation</p></td><td><p>23%</p></td><td><p>17%</p></td></tr><tr><td><p>Insomnia</p></td><td><p>20%</p></td><td><p>19%</p></td></tr><tr><td><p>Nervousness</p></td><td><p>16%</p></td><td><p>14%</p></td></tr><tr><td><p>Hostility</p></td><td><p>15%</p></td><td><p>14%</p></td></tr><tr><td><p>Dizziness<sup>2</sup></p></td><td><p>11%</p></td><td><p>4%</p></td></tr><tr><td><p>Anxiety</p></td><td><p>9%</p></td><td><p>8%</p></td></tr><tr><td><p>Personality disorder</p></td><td><p>8%</p></td><td><p>4%</p></td></tr><tr><td><p>Akathisia<sup>2</sup></p></td><td><p>5%</p></td><td><p>1%</p></td></tr><tr><td><p>Hypertonia</p></td><td><p>4%</p></td><td><p>3%</p></td></tr><tr><td><p>Speech disorder</p></td><td><p>4%</p></td><td><p>1%</p></td></tr><tr><td><p>Tremor</p></td><td><p>4%</p></td><td><p>3%</p></td></tr><tr><td><p>Amnesia</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>Drug dependence</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>Euphoria</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>Neurosis</p></td><td><p>1%</p></td><td><p>0%</p></td></tr><tr><td colspan="3"><p><strong><em>Respiratory</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Rhinitis</p></td><td><p>10%</p></td><td><p>6%</p></td></tr><tr><td><p>Cough increased</p></td><td><p>5%</p></td><td><p>3%</p></td></tr><tr><td><p>Pharyngitis</p></td><td><p>5%</p></td><td><p>3%</p></td></tr><tr><td colspan="3"><p><strong><em>Skin and Appendages</em></strong></p></td></tr><tr><td><p>Fungal dermatitis</p></td><td><p>2%</p></td><td><p>0%</p></td></tr><tr><td><p>Vesiculobullous rash</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td colspan="3"><p><strong><em>Special</em></strong><strong><em> Senses</em></strong></p></td></tr><tr><td><p>Amblyopia</p></td><td><p>5%</p></td><td><p>4%</p></td></tr><tr><td><p>Blepharitis</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Eye disorder</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Corneal lesion</p></td><td><p>1%</p></td><td><p>0%</p></td></tr><tr><td colspan="3"><p><strong><em>Urogenital System</em></strong></p></td></tr><tr><td><p>Menstrual disorder<sup>3</sup></p></td><td><p>2%</p></td><td><p>0%</p></td></tr></tbody></table><p>The following events had an incidence equal to or less than placebo: abnormal dreams, accidental injury, anorexia, apathy, asthenia, cogwheel rigidity, confusion, conjunctivitis, depression, diarrhea, dysmenorrhea<sup>3</sup>, dyspepsia, ecchymosis, emotional lability, hallucinations, hyperkinesia, hypertension, hypokinesia, libido increased, myalgia, nausea, paranoid reaction, paresthesia, pruritus, rash, schizophrenic reaction, sweating, thinking abnormal, tooth caries, vaginitis<sup>3</sup>, vomiting.</p><p>Statistically significantly more frequent in patients treated with olanzapine than in patients treated with placebo.</p><p>Denominator used was for females only (N=4l Olanzapine; N=23 Placebo).</p><p>&nbsp;</p><p><u>Other Adverse Events from Schizophrenia Trials:</u></p><p>Certain portions of the discussion below relating to objective or numeric safety parameters, namely, vital sign changes, weight gain, laboratory changes, and ECG changes are derived from studies in patients with schizophrenia and have not been duplicated for bipolar mania. However, this information is also generally applicable to bipolar mania.</p><p>&nbsp;</p><p><em>Weight</em><em> Changes:</em></p><p>During acute therapy (up to 6 weeks) in controlled clinical trials comparing olanzapine with placebo in the treatment of schizophrenia, the percentages of patients with weight gain &ge; 7% of baseline body weight at any time were 29% for olanzapine and 3% for placebo, which was a statistically significant difference. The average weight gain during acute therapy in patients treated with olanzapine was 2.8 kg. Clinically significant weight gain was observed across all baseline body mass index (BMI) categories. In long-term extension schizophrenia trials, there was an average gain of 5.4 kg, and 56% of olanzapine-treated patients with weight gain &gt;7% of baseline body weight. In long-term extension bipolar maintenance trials, there was a mean weight gain of 3.8 kg, and with 31% of olanzapine-treated patients with weight gain &gt;7% of baseline body weight (see 4.4, Endocrine and Metabolism subsection).</p><p>&nbsp;</p><p><em>Vital Sign Changes:</em></p><p>In placebo-controlled clinical trials, orthostatic hypotension (greater than 30 mm decrease in systolic blood pressure) occurred with an incidence of 5% in oral olanzapine-treated patients compared to 2% in placebo-treated patients (vital sign measurements collected only after 3-7 days of olanzapine treatment). Oral olanzapine was associated with a mean baseline to endpoint increase in heart rate of 2.4 beats per minute compared to no change among placebo-treated patients (see 4.4, Cardiovascular subsection).</p><p>&nbsp;</p><p><em>Laboratory Changes:</em></p><p>Olanzapine is associated with asymptomatic increases in SGPT, SGOT, and GGT (see 4.4, Hepatic subsection). Olanzapine is also associated with generally mild increases in serum prolactin, which usually decreases with continued drug treatment. Olanzapine is also associated with asymptomatic elevations of eosinophils and uric acid (see 4.4, Renal subsection), and with decreases in serum bicarbonate.</p><p>&nbsp;</p><p><em>ECG Changes:</em></p><p>Between-group comparisons for pooled placebo-controlled trials revealed no statistically significant olanzapine/placebo differences in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc, and PR intervals.</p><p>&nbsp;</p><p><strong><u>Other Adverse Events Observed During Clinical Trials with Oral and Intramuscular</u> <u>Olanzapine Across All Indications</u></strong></p><p>The following discussion relates primarily to weight gain, lipids, and glucose changes observed during clinical trials across all indications.</p><p>&nbsp;</p><p><em>Weight</em><em> Changes</em>:</p><p>Weight gain has been very commonly observed in olanzapine-treated patients during clinical trials. In 13 placebo-controlled olanzapine monotherapy studies, 22.2% of olanzapine-treated patients gained &ge; 7% of their baseline body weight versus 3% of placebo-treated patients, with a median exposure of 8 weeks; 4.2% of olanzapine-treated patients gained &ge; 15% of their baseline weight versus 0.3% of placebo-treated patients, with a median exposure to event of 12 weeks.</p><p>Clinically significant weight gain was observed across all baseline body mass index (BMI) categories.</p><p>In long-term studies (at least 48 weeks), both the magnitude of weight gain and the proportion of olanzapine-treated patients who had clinically significant weight gain were greater than in short- term studies. The percentage of patients who gained &ge;25% of their baseline body weight with long-term exposure was very common (&ge;10%).</p><p>&nbsp;</p><p><em>Lipids:</em></p><p>In placebo-controlled clinical trials of up to 12 weeks in duration, olanzapine-treated patients had a greater mean increase in fasting total cholesterol, LDL cholesterol, and triglycerides compared to placebo-treated patients.</p><p>Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline. However, for mean changes in fasting triglycerides, the difference between olanzapine and placebo was greater in patients with evidence of lipid dysregulation at baseline. Elevations in fasting triglyceride levels &ge; 11.3 mmol/L were uncommonly observed with olanzapine use (8 week median duration of exposure).</p><p>&nbsp;</p><p><strong>Table 2: Changes in Fasting Lipids Values from Adult Placebo-Controlled Olanzapine Monotherapy Studies with Treatment Duration up to 12 Weeks</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Laboratory</strong><strong> Analyte</strong></p></td><td><p><strong>Olanzapine*</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Triglycerides: fasting normal to high (&lt; 1.70 mmol/L to &ge; 2.26 mmol/L)</p></td><td><p>9.2%</p><p>(N=457)</p></td><td><p>4.4%</p><p>(N=251)</p></td></tr><tr><td><p>Triglycerides: fasting borderline to high (&ge; 1.70 mmol/L and &lt; 2.26 mmol/L to &ge; 2.26 mmol/L)</p></td><td><p>39.3%</p><p>(N=135)</p></td><td><p>20.0%</p><p>(N=65)</p></td></tr><tr><td><p>Cholesterol-Total: fasting normal to high (&lt;5.18 mmol/L to &ge; 6.22 mmol/L)</p></td><td><p>2.8%</p><p>(N=392)</p></td><td><p>2.4%</p><p>(N=207)</p></td></tr><tr><td><p>Cholesterol-Total: fasting borderline to high (&ge; 5.18 mmol/L and &lt; 6.22 mmol/L to &ge; 6.22 mmol/L)</p></td><td><p>23.0%</p><p>(N=222)</p></td><td><p>12.5%</p><p>(N=112)</p></td></tr><tr><td><p>LDL cholesterol: fasting normal to high (&lt;2.59mmol/L to &ge; 4.14 mmol/L)</p></td><td><p>0%</p><p>(N=154)</p></td><td><p>1.2%</p><p>(N=82)</p></td></tr><tr><td><p>LDL cholesterol: fasting borderline to high (&ge;2.59 mmol/L and &lt; 4.14 mmol/L to &ge; 4.14 mmol/L)</p></td><td><p>10.6%</p><p>(N=302)</p></td><td><p>8.1%</p><p>(N=173)</p></td></tr></tbody></table><p>* Median duration of exposure 8 weeks.</p><p>For fasting HDL cholesterol, no statistically significant differences were observed between olanzapine-treated patients and placebo-treated patients (see 4.4, Endocrine and Metabolism subsection).</p><p>The proportion of patients who had changes in total cholesterol, LDL cholesterol or triglycerides from normal or borderline to high, or changes in HDL cholesterol from normal or borderline to low, was greater in long-term studies (at least 48 weeks) as compared with short-term studies.</p><p>Treatment-emergent clinically significant changes in fasting lipids were observed in patients with or without evidence of dyslipidemia at baseline.</p><p>&nbsp;</p><p><em>Glucose Changes</em>:</p><p>In clinical trials (up to 52 weeks) olanzapine was associated with a greater mean change in glucose relative to placebo.</p><p>The difference in mean changes between olanzapine and placebo was greater in patients with evidence of glucose dysregulation at baseline (including those patients diagnosed with diabetes mellitus or who met criteria suggestive of hyperglycemia), and these patients had a greater increase in HbA1c compared to placebo.</p><p>In patients with baseline normal fasting glucose levels (&lt;5.5mmol/L), 2.2% (N=543) of those treated with olanzapine (median exposure duration of 8 weeks) were found to have high glucose levels (&ge; 6.99 mmol/L) during olanzapine treatment versus 3.4% (N=293) of those treated with placebo. In patients with baseline borderline fasting glucose levels (&ge; 5.5 mmol/L and &lt; 6.99 mmol/L), 17.4% (N=178) of those treated with olanzapine (median exposure duration of 5 weeks) were found to have high glucose levels (&ge; 6.99 mmol/L) during olanzapine treatment versus 11.5% (N=96) of those treated with placebo.</p><p>The proportion of patients who had a change in glucose level from normal or borderline at baseline to high increased over time. Treatment-emergent clinically significant changes in fasting glucose were observed in patients with or without evidence of glucose dysregulation at baseline.</p><p>Glycosuria was commonly reported in olanzapine-treated patients during clinical trials.</p><p>&nbsp;</p><p><em>Prolactin:</em></p><p>In controlled clinical trials (up to 12 weeks), elevations in prolactin were observed in 30% of olanzapine-treated patients as compared to 10.5% of placebo-treated patients. In the majority of these patients, the elevations were mild. In patients with schizophrenia, menstrual-related adverse events potentially associated with prolactin elevations1 were common (&lt;10% to &ge;1%), whereas sexual function-related and breast-related adverse events were infrequent (&lt;1% to &ge;0.1%). In patients treated for other mental illnesses2, sexual function-related adverse events (erectile dysfunction, libido decreased, loss of libido, orgasm abnormal) potentially associated with prolactin elevations were common (&lt;10% to &ge;1%), whereas breast-related and menstrual- related adverse events were infrequent (&lt;1% to &ge;0.1%).</p><p><em>(1)&nbsp;</em><em>TEAEs analysis up to 52 weeks of treatment</em></p><p><em>(2)&nbsp;</em><em>Bipolar</em><em> Depression, Psychotic Depression, Borderline Personality Disorder and Bipolar Mania</em></p><p><em>Vital Sign Changes</em>:</p><p>Bradycardia was uncommonly observed in clinical trials.</p><p><em>Photosensitivity Reactions:</em></p><p>Photosensitivity reactions were uncommonly observed in clinical trials.</p><p>Table 3 summarizes core adverse drug reaction terms and their frequencies identified from an integrated database of 42 completed olanzapine clinical studies in adults, consisting of 7787 patients exposed to olanzapine in placebo- or comparator-controlled clinical studies.</p><p>&nbsp;</p><p><strong>Table 3: Core Adverse Drug Reactions from Clinical Trials of Olanzapine</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System/Adverse Reactions Term</strong></p></td><td colspan="5"><p><strong>Frequency</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&ge;10%</p></td><td><p>&lt;10% and &ge;1%</p></td><td><p>&lt;1% and &ge;0.1%</p></td><td><p>&lt;0.1% and &ge;0.01%</p></td><td><p>&lt;0.01%</p></td></tr><tr><td colspan="6"><p><strong><em>Body as a Whole</em></strong></p></td></tr><tr><td><p>Pyrexia</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Cardiovascular</em></strong></p></td></tr><tr><td><p><sup>1</sup>Orthostatic Hypotension</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Digestive System</em></strong></p></td></tr><tr><td><p>Abdominal Distension</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Musculoskeletal</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Arthralgia</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Nervous</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Amnesia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Respiratory,</em></strong><strong><em> Thoracic and Mediastinal Disorders</em></strong></p></td></tr><tr><td><p>Epistaxis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Laboratory Analytes</em></strong></p></td></tr><tr><td colspan="6"><p><em>Clinical Chemistry</em></p></td></tr><tr><td><p><sup>1</sup>Alkaline phosphatase-Increased</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><sup>1</sup>Gamma Glutamyltransferase (GGT)</p><p>(U/L)- High</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><sup>1</sup>Uric Acid (&mu;mol/L)-High</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><em>Hematology</em></p></td></tr><tr><td><p><sup>1</sup>Leukopenia, including Neutropenia</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>As assessed by measured values within the clinical trial database.</p><p>&nbsp;</p><p><strong><u>Dose-Dependent Adverse Events:</u></strong></p><p>Dose-relatedness of adverse events was assessed using data from a clinical trial with a fixed dosage range. Table 4 enumerates the treatment-emergent adverse events in which there was a statistically significantly increasing dose response in this clinical trial.</p><p>&nbsp;</p><p><strong>Table 4: Schizophrenia Trials: Dose-Dependent Adverse Events in a Fixed Dosage Range, Placebo-Controlled Clinical Trial<sup>1</sup>&nbsp;</strong><strong>of</strong><strong> </strong><strong>Oral Olanzapine</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="4"><p><strong>Percentage</strong><strong> </strong><strong>of Patients Reporting Event</strong></p></td></tr><tr><td><p><strong>&nbsp;Body System/Adverse Event</strong></p></td><td><p><strong>&nbsp;Placebo<strong> </strong>(N=68)</strong></p></td><td><p><strong>Olanzapine 5 &plusmn; 2.5 mg/day<strong> </strong>(N=65)</strong></p></td><td><p><strong>Olanzapine 10 &plusmn; 2.5 mg/day<strong> </strong>(N=64)</strong></p></td><td><p><strong>Olanzapine 15 &plusmn; 2.5 mg/day<strong> </strong>(N=69)</strong></p></td></tr><tr><td colspan="5"><p><strong><em>Digestive System</em></strong></p></td></tr><tr><td><p>Constipation</p></td><td><p>0%</p></td><td><p>6.2%</p></td><td><p>9.4%</p></td><td><p>14.5%</p></td></tr><tr><td colspan="5"><p><strong><em>Nervous</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Abnormal dreams</p></td><td><p>0%</p></td><td><p>0%</p></td><td><p>1.6%</p></td><td><p>4.3%</p></td></tr><tr><td><p>Dizziness</p></td><td><p>2.9%</p></td><td><p>7.7%</p></td><td><p>9.4%</p></td><td><p>17.4%</p></td></tr><tr><td><p>Somnolence</p></td><td><p>16.2%</p></td><td><p>20.0%</p></td><td><p>29.7%</p></td><td><p>39.1%</p></td></tr><tr><td colspan="5"><p><strong><em>Respiratory</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Pharyngitis</p></td><td><p>1.5%</p></td><td><p>3.1%</p></td><td><p>1.6%</p></td><td><p>10.1%</p></td></tr></tbody></table><p><sup>1</sup>Fungal dermatitis was also reported with a statistically significantly increasing dose response, but is not included as a drug cause was remote.</p><p>&nbsp;</p><p>Table 5 enumerates the treatment-emergent adverse events from one 8-week, randomized, double-blind, fixed-dose trial comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of olanzapine in patients with schizophrenia or schizoaffective disorder. Statistically significant differences among the 3 dose groups were observed for the following safety outcomes: fatigue, dizziness, prolactin elevation, and weight gain (mean change).</p><p>&nbsp;</p><p><strong>Table 5: Schizophrenia Trials: Dose-Dependent Adverse Events in a Fixed Dose, Placebo-Controlled Clinical Trial<sup>1</sup> of</strong><strong> </strong><strong>Oral Olanzapine</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;Adverse Event</strong></p></td><td><p><strong>Olanzapine 10 mg/day (N=195)</strong></p></td><td><p><strong>Olanzapine 20 mg/day (N=191)</strong></p></td><td><p><strong>Olanzapine 40 mg/day (N=197)</strong></p></td></tr><tr><td><p>Fatigue<sup>2,</sup><sup>3</sup>&nbsp;(% reporting event)</p></td><td><p>1.5%</p></td><td><p>2.1%</p></td><td><p>6.6%</p></td></tr><tr><td><p>Dizziness<sup>3</sup> (% reporting event)</p></td><td><p>2.6%</p></td><td><p>1.6%</p></td><td><p>6.6%</p></td></tr><tr><td><p>Prolactin Elevation<sup>2,3,4</sup>&nbsp;(% reporting event)</p></td><td><p>31.2%</p></td><td><p>42.7%</p></td><td><p>61.1%</p></td></tr><tr><td><p>Prolactin Elevation<sup>2,</sup><sup>3</sup>&nbsp;(mean change from baseline to endpoint)</p></td><td><p>-10.5</p><p>ng/mL</p></td><td><p>-1.7 ng/mL</p></td><td><p>4.9 ng/mL</p></td></tr><tr><td><p>Weight Gain &ge;7% at any time (% reporting event)</p></td><td><p>14.0%</p></td><td><p>18.4%</p></td><td><p>20.5%</p></td></tr><tr><td><p>Weight Gain<sup>2</sup>&nbsp;(mean change from baseline to endpoint)</p></td><td><p>1.9 kg</p></td><td><p>2.3 kg</p></td><td><p>3.0 kg</p></td></tr></tbody></table><p>1. Study HGLF: 8-week, Phase IV, parallel, randomized, double-blind, fixed-dose study in patients with schizophrenia and schizoaffective disorder evaluating the dose-response efficacy and safety of olanzapine 10, 20, and 40 mg/day. Patients were titrated up to their randomized dose over 2 weeks.</p><p>2. significant difference between 10 vs. 40 mg/day</p><p>3. significant difference between 20 vs. 40 mg/day</p><p>4. &gt;24.2 ng/mL (female) or &gt;18.77 ng/mL (male) at any time during the trial</p><p>&nbsp;</p><p><u>Incidence of Treatment-Emergent Extrapyramidal Symptoms:</u></p><p>Table 6 enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by categorical analyses of formal rating scales during acute therapy in a controlled clinical trial comparing oral olanzapine at 3 fixed dosage ranges with placebo in the treatment of schizophrenia.</p><p><strong>Table 6: Schizophrenia Trials: Treatment-Emergent Extrapyramidal Symptoms Assessed By Rating Scales Incidence In A Fixed Dosage Range, Placebo- Controlled Clinical Trial -- Acute Phase<sup>1</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p></td><td colspan="4"><p><strong>Percentage</strong><strong> </strong><strong>of Patients</strong></p></td></tr><tr><td><p><strong>&nbsp;Placebo</strong></p></td><td><p><strong>Olanzapine 5 &plusmn; 2.5</strong></p><p><strong>mg/day</strong></p></td><td><p><strong>Olanzapine 10 &plusmn; 2.5</strong></p><p><strong>mg/day</strong></p></td><td><p><strong>Olanzapine 15 &plusmn; 2.5</strong></p><p><strong>mg/day</strong></p></td></tr><tr><td><p>Parkinsonism<sup>2</sup></p></td><td><p>15%</p></td><td><p>14%</p></td><td><p>12%</p></td><td><p>14%</p></td></tr><tr><td><p>Akathisia<sup>3</sup></p></td><td><p>23%</p></td><td><p>16%</p></td><td><p>19%</p></td><td><p>27%</p></td></tr></tbody></table><p>1.&nbsp;&nbsp;&nbsp;&nbsp; No statistically significant differences.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Percentage of patients with a Simpson-Angus Scale total score &ge;3.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Percentage of patients with a Barnes Akathisia Scale global score &ge;2.</p><p>&nbsp;</p><p>Table 7 enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse events during acute therapy in the same controlled clinical trial comparing oral olanzapine at 3 fixed dosage ranges with placebo in the treatment of schizophrenia. Similar results were found during the long-term (up to 1-year) double-blind monotherapy extension bipolar maintenance trial comparing olanzapine with placebo; there was a higher statistical incidence of akathisia for combined doses of olanzapine versus placebo.</p><p>&nbsp;</p><p><strong>Table 7: Schizophrenia Trials: Treatment-Emergent Extrapyramidal Symptoms Assessed by Adverse Events Incidence in an Oral Fixed Dosage Range, Placebo-Controlled Clinical Trial &mdash;Acute Phase<sup>1</sup></strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:66.1pt;margin-top:-161.05pt;width:480.5pt;
 height:175.45pt;z-index:1144;mso-position-horizontal-relative:page' filled="f"
 stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Extrapyramidal<strong> </strong>Symptoms</strong></p></td><td colspan="4"><p><strong>Percentage</strong><strong> </strong><strong>of Patients Reporting Event</strong></p></td></tr><tr><td><p><strong>Placebo</strong></p><p><strong>(N=68)</strong></p></td><td><p><strong>Olanzapine </strong></p><p><strong>5 &plusmn; 2.5 mg/day</strong></p><p><strong>(N=65)</strong></p></td><td><p><strong>Olanzapine</strong></p><p><strong>10 &plusmn; 2.5 mg/day</strong></p><p><strong>(N=64)</strong></p></td><td><p><strong>Olanzapine </strong></p><p><strong>15 &plusmn; 2.5 mg/day</strong></p><p><strong>(N=69)</strong></p></td></tr><tr><td><p>Dystonic events<sup>2</sup></p></td><td><p>1%</p></td><td><p>3%</p></td><td><p>2%</p></td><td><p>3%</p></td></tr><tr><td><p>Parkinsonism events<sup>3</sup></p></td><td><p>10%</p></td><td><p>8%</p></td><td><p>14%</p></td><td><p>20%</p></td></tr><tr><td><p>Akathisia events<sup>4</sup></p></td><td><p>1%</p></td><td><p>5%</p></td><td><p>11%<sup>1</sup></p></td><td><p>10%<sup>1</sup></p></td></tr><tr><td><p>Dyskinetic events<sup>5</sup></p></td><td><p>4%</p></td><td><p>0%</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Residual events<sup>6</sup></p></td><td><p>1%</p></td><td><p>2%</p></td><td><p>5%</p></td><td><p>1%</p></td></tr><tr><td><p>Any extrapyramidal event</p></td><td><p>16%</p></td><td><p>15%</p></td><td><p>25%</p></td><td><p>32%<sup>1</sup></p></td></tr></tbody></table><p>1.&nbsp;&nbsp; &nbsp;Statistically significantly different from placebo.</p><p>2.&nbsp;&nbsp; &nbsp;Patients with the following COSTART terms were counted in this category: dystonia, generalized spasm, neck rigidity, oculogyric crisis, opisthotonos, torticollis.</p><p>3.&nbsp;&nbsp; &nbsp;Patients with the following COSTART terms were counted in this category: akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor.</p><p>4.&nbsp;&nbsp; &nbsp;Patients with the following COSTART terms were counted in this category: akathisia, hyperkinesia.</p><p>5.&nbsp;&nbsp; &nbsp;Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, choreoathetosis, dyskinesia, tardive dyskinesia.</p><p>6.&nbsp;&nbsp; &nbsp;Patients with the following COSTART terms were counted in this category: movement disorder, myoclonus, twitching.</p><p>&nbsp;</p><p><strong><u>Other Investigational Trials</u></strong></p><p><em><u>Cerebrovascular</u></em><em><u> Adverse Events (CVAEs) in Elderly Patients with Dementia</u></em></p><p>Data from <em>5 </em>placebo-controlled trials in elderly patients with dementia-related psychosis (Alzheimer&rsquo;s, vascular, and mixed; olanzapine n=1178 and placebo n=478) suggest that there was a higher incidence of CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). Although the incidence of CVAE was not significantly different when analyzed with Fisher&rsquo;s Exact Test (p=0.177), the difference was found to be significant when simultaneously controlling for age, gender, and type of dementia using Poisson Regression (p=0.0428). Four patients died in the olanzapine group versus 1 patient in the placebo group. In open-label safety trials studied for up to 59 weeks in dementia patients (N=231), 7 cases of CVAEs, including 2 fatalities, were reported (see 4.4).</p><p>Data from these trials suggest that patients with a dementia diagnosis of vascular or mixed type had a 5-fold higher likelihood of experiencing CVAEs than patients with a diagnosis of Alzheimer&rsquo;s. There is insufficient information to determine whether CVAEs in elderly patients with dementia are associated specifically with olanzapine or all antipsychotic agents.</p><p>Olanzapine is not approved for use in elderly patients with dementia.</p><p>&nbsp;</p><p><em><u>Overall</u></em><em><u> Mortality</u></em></p><p>Elderly patients with dementia treated with atypical antipsychotic drugs showed increased mortality compared to placebo in a meta-analysis of 13 controlled trials of various atypical antipsychotic drugs. In five placebo-controlled trials with oral olanzapine in this population, the incidence of mortality was 3.5% for olanzapine-treated patients compared to 1.5% for placebo- treated patients. Olanzapine is not indicated in elderly patients with dementia.</p><p>&nbsp;</p><p><em><u>Laboratory Changes</u></em></p><p>In 5 double-blind, placebo controlled clinical trials of elderly patients with dementia-related psychosis (n = 1184 total in the olanzapine arms and n = 478 total in placebo arms), olanzapine- treated patients showed significantly greater incidence rates compared to placebo-treated patients of low albumin (10.4% vs 5.5%, respectively), low hemoglobin (4.2% vs 1.8%) and low hematocrit (4.6% vs 2.4%). Of patients who had low albumin values, 3.6% in the olanzapine- treated group vs 1.4% in the placebo-treated also experienced a treatment-emergent respiratory infection. A causal relationship between the two adverse events has not been determined.</p><p>&nbsp;</p><p><em><u>Adverse</u></em><em><u> Events in Adolescent Patients (ages 13-17 years)</u></em></p><p>The types of adverse events observed in adolescent patients treated with olanzapine were similar to those seen in adult patients. Although no clinical trials designed to compare adolescents to adults were conducted, the data from the adolescent trials were compared to those of the adult trials.</p><p>Mean increase in weight in adolescents (4.6 kg over 3 weeks median duration of exposure) was greater than in adults (2.6 kg over 7 weeks median duration of exposure).</p><p>In long-term studies (at least 24 weeks), both the magnitude of weight gain and the proportion of adolescent olanzapine-treated patients who had clinically significant weight gain were greater than in short-term studies and were greater than in adult patients with comparable exposures.</p><p>With long-term exposure, approximately half of adolescent patients gained &ge;15% and almost a third gained &ge;25% of their baseline body weight. Among adolescent patients, mean weight gain was greatest in patients who were overweight or obese at baseline.</p><p>Mean increases in fasting glucose were similar in adolescents and adults treated with olanzapine; however, the difference between olanzapine and placebo groups was greater in adolescents compared to adults.</p><p>In long-term studies (at least 24 weeks), changes in glucose from normal at baseline to high were uncommon (&lt;1% and &ge;0.1%).</p><p>Mean increases in fasting total cholesterol, LDL cholesterol, and triglycerides were generally greater in adolescents than in adults treated with olanzapine. However, in short term trials, the differences between olanzapine and placebo were similar for adolescents and adults. The proportion of treatment-emergent clinically significant changes in normal-to-high or borderline- to-high fasting total cholesterol, LDL cholesterol and triglycerides was greater in adolescents compared to adults, and the differences between olanzapine and placebo in these categories of laboratory values were also generally greater in adolescents. In long-term studies, treatment- emergent clinically significant changes in total cholesterol, LDL cholesterol, and triglycerides were observed in adolescents with or without evidence of dyslipidemia at baseline.</p><p>Compared with adults, adolescents treated with olanzapine experienced a significantly higher incidence of elevated prolactin levels (47% in olanzapine-treated adolescents vs 30% in olanzapine-treated adults) and significantly higher mean increases in prolactin levels.</p><p>Hepatic aminotransferase elevations (3 times the Upper limit of Normal) are more common in adolescents (12.1%) as compared to adults (5.4%).</p><p>Sedation-related events are more common in adolescents (44%) as compared to adults (29%).</p><p>Table 8 summarizes core adverse drug reaction terms for olanzapine compared to placebo and their frequencies identified only during clinical trials in adolescent patients (ages 13 to 17 years). Olanzapine is not indicated in adolescent patients (ages 13-17 years).</p><p><strong>Table 8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Core Adverse Drug Reactions and Frequencies from Clinical Trials in Adolescent Patients (ages 13-17 years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System / Adverse Reaction Term</strong></p></td><td colspan="2"><p><strong>Olanzapine</strong></p></td><td colspan="2"><p><strong>Placebo</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>N</strong></p></td></tr><tr><td colspan="5"><p><strong><em>Body as a Whole</em></strong></p></td></tr><tr><td><p>Weight gain &ge;7% of baseline body weight (kg) <sup>7</sup></p></td><td><p>40.6%</p></td><td><p>197</p></td><td><p>9.8%</p></td><td><p>112</p></td></tr><tr><td><p>Weight gain &ge;15% of baseline body weight (kg) <sup>8</sup></p></td><td><p>7.1%</p></td><td><p>197</p></td><td><p>2.7%</p></td><td><p>112</p></td></tr><tr><td colspan="5"><p><strong><em>Digestive System</em></strong></p></td></tr><tr><td><p>Dry Mouth</p></td><td><p>6.15%</p></td><td><p>179</p></td><td><p>0%</p></td><td><p>89</p></td></tr><tr><td><p>Increased Appetite</p></td><td><p>24%</p></td><td><p>179</p></td><td><p>6%</p></td><td><p>89</p></td></tr><tr><td colspan="5"><p><strong><em>Nervous</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Sedation <sup>1</sup></p></td><td><p>44.1%</p></td><td><p>179</p></td><td><p>9%</p></td><td><p>89</p></td></tr><tr><td colspan="5"><p><strong><em>Clinical Chemistry</em></strong></p></td></tr><tr><td><p>ALT/SGPT &gt;3X ULN all randomized patients with ALT baseline &lt;= 3X ULN <sup>3</sup></p></td><td><p>12.1%</p></td><td><p>174</p></td><td><p>2.3%</p></td><td><p>87</p></td></tr><tr><td><p>AST/SGOT &ndash; Increased <sup>3</sup></p></td><td><p>27.6%</p></td><td><p>163</p></td><td><p>3.8%</p></td><td><p>79</p></td></tr><tr><td><p>Total bilirubin &ndash;Decreased <sup>4</sup></p></td><td><p>22.1%</p></td><td><p>154</p></td><td><p>6.7%</p></td><td><p>75</p></td></tr><tr><td><p>GGT - Increased <sup>5</sup></p></td><td><p>10.1%</p></td><td><p>169</p></td><td><p>1.2%</p></td><td><p>83</p></td></tr><tr><td><p>Prolactin &ndash; Increased <sup>6</sup></p></td><td><p>47.4%</p></td><td><p>116</p></td><td><p>6.8%</p></td><td><p>59</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System / Adverse Reaction Term</strong></p></td><td colspan="2"><p><strong>Olanzapine</strong></p></td><td colspan="2"><p><strong>Placebo</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>N</strong></p></td></tr><tr><td><p>Cholesterol &ndash; total, fasting normal to high (&lt;4.40 mmol/L to &ge;5.18 mmol/L) <sup>9</sup></p></td><td><p>6.9%</p></td><td><p>87</p></td><td><p>2.3%</p></td><td><p>43</p></td></tr><tr><td><p>Cholesterol &ndash; total, fasting borderline to high (&ge;4.40 mmol/L and &lt;5.18 mmol/L to &ge;5.18 mmol/L)&nbsp;<sup>9</sup></p></td><td><p>38.9%</p></td><td><p>36</p></td><td><p>7.7%</p></td><td><p>13</p></td></tr><tr><td><p>LDL cholesterol: fasting normal to high (&lt;2.85 mmol/L to &ge;3.37 mmol/L)</p></td><td><p>5.1%</p></td><td><p>98</p></td><td><p>4.5%</p></td><td><p>44</p></td></tr><tr><td><p>LDL cholesterol: fasting borderline to high (&ge;2.85 mmol/L and &lt; 3.37 mmol/L to &ge; 3.37 mmol/L)</p></td><td><p>48.3%</p></td><td><p>29</p></td><td><p>0%</p></td><td><p>9</p></td></tr><tr><td><p>Triglycerides, fasting normal to high (&lt;1.02 mmol/L to &gt;1.47 mmol/L) <sup>9</sup></p></td><td><p>26.9%</p></td><td><p>67</p></td><td><p>10.7%</p></td><td><p>28</p></td></tr><tr><td><p>Triglycerides, fasting borderline to high (&ge;1.02 mmol/L and &le;1.47 mmol/L to &gt;1.47 mmol/L) <sup>9</sup></p></td><td><p>59.5%</p></td><td><p>37</p></td><td><p>35.3%</p></td><td><p>17</p></td></tr><tr><td><p>Glucose, fasting normal to high (&lt;5.55 mmol/L to &ge;6.99 mmol/L) <sup>9</sup></p></td><td><p>0%</p></td><td><p>124</p></td><td><p>1.9%</p></td><td><p>53</p></td></tr><tr><td><p>Glucose, fasting borderline to high (&ge;5.55 mmol/L and &lt;6.99 mmol/L to &ge;6.99 mmol/L) <sup>10</sup></p></td><td><p>14.3%</p></td><td><p>14</p></td><td><p>0%</p></td><td><p>13</p></td></tr></tbody></table><p>1 = Represented cluster of MedDRA terms including: hypersomnia, lethargy, sedation, somnolence.</p><p>2 = Covance reference ranges:&nbsp;&nbsp;Low&nbsp;&nbsp;High</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>(U/L)</p></td><td><p>Female 13 - &le; 17.999</p></td><td><p>6</p></td><td><p>34</p></td></tr><tr><td><p>(U/L)</p></td><td><p>Male 13 - &le; 17.999</p></td><td><p>6</p></td><td><p>43</p></td></tr></tbody></table><p>&nbsp;</p><p>3 = Covance reference ranges:&nbsp;&nbsp;Low&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>(U/L)</p></td><td><p>Female 13 - &le; 17.999</p></td><td><p>10</p></td><td><p>40</p></td></tr><tr><td><p>(U/L)</p></td><td><p>Male 13 - &le; 17.999</p></td><td><p>10</p></td><td><p>40</p></td></tr></tbody></table><p>&nbsp;</p><p>4 = Covance reference ranges:&nbsp; &nbsp; &nbsp; &nbsp; Low&nbsp;&nbsp;&nbsp;High</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>(mmol/L)</p></td><td><p>Female 13 - &le; 17.999</p></td><td><p>3</p></td><td><p>21</p></td></tr><tr><td><p>(mmol/L)</p></td><td><p>Male 13 - &le; 17.999</p></td><td><p>3</p></td><td><p>21</p></td></tr></tbody></table><p>&nbsp;</p><p>5 = Covance reference ranges&nbsp; Low&nbsp;&nbsp;High</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>(U/L)</p></td><td><p>Female 13 - &le; 17.999</p></td><td><p>0</p></td><td><p>33</p></td></tr><tr><td><p>(U/L)</p></td><td><p>Male 13 - &le; 17.999</p></td><td><p>0</p></td><td><p>51</p></td></tr></tbody></table><p>6 = Covance reference ranges for prolactin as published by Wiedemann and Jonetz-Mentzel (1993)</p><p><strong>Female: </strong></p><p>12 to 14 years: 2.52 &ndash; 16.90 ng/mL</p><p>14 to 19 years: 4.20 &ndash; 39.00 ng/mL</p><p><strong>Male: </strong></p><p>12 to 14 years: 2.84 &ndash; 24.00 ng/mL</p><p>14 to 19 years: 2.76 &ndash; 16.10 ng/mL</p><p>7 = Median duration of exposure to event = 4 weeks</p><p>8 = Median duration of exposure to event =19 weeks</p><p>9 = Median duration of exposure was 3 weeks</p><p>10 = Median duration of exposure was 5 weeks</p><p>&nbsp;</p><p><strong><u>Post-Market</u></strong><strong><u> Adverse Drug Reactions</u></strong></p><p>Table 9 summarizes core adverse drug reaction terms and their frequencies identified from global post-marketing surveillance in addition to what was reported in clinical trials (see preceding section 4.8, Clinical Trial Adverse Drug Reactions). A causal relationship between olanzapine and the emergence of these events has not been established.</p><p><strong>Table 9: Core Adverse Drug Reactions Seen with Olanzapine Formulations<sup>1</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System /Adverse Reaction Term</strong></p></td><td colspan="5"><p><strong>Frequency</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&ge;10%</p></td><td><p>&lt;10% and &ge;1%</p></td><td><p>&lt;1% and &ge;0.1%</p></td><td><p>&lt;0.1% and &ge;0.01%</p></td><td><p><strong>&nbsp;</strong>&lt;0.01%</p></td></tr><tr><td colspan="6"><p><strong><em>Body as a Whole</em></strong></p></td></tr><tr><td><p>Allergic reaction <sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Discontinuation reaction <sup>3</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Cardiovascular</em></strong></p></td></tr><tr><td><p>Venous Thromboembolism, including Pulmonary Embolism and Deep Vein Thrombosis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Digestive System</em></strong></p></td></tr><tr><td><p>Pancreatitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Hematologic</em></strong></p></td></tr><tr><td><p>Thrombocytopenia <sup>4</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Hepatobiliary disorders</em></strong></p></td></tr><tr><td><p>Hepatitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Jaundice</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Hepatic failure</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Metabolic</em></strong></p></td></tr><tr><td><p>Diabetic Coma</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body System /Adverse Reaction Term</strong></p></td><td colspan="5"><p><strong>Frequency</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&ge;10%</p></td><td><p>&lt;10% and &ge;1%</p></td><td><p>&lt;1% and &ge;0.1%</p></td><td><p>&lt;0.1% and &ge;0.01%</p></td><td><p>&lt;0.01%</p></td></tr><tr><td><p>Diabetic Ketoacidosis <sup>5</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Hypercholesterolemia&nbsp;<sup>7</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Hyperglycaemia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypertriglyceridemia <sup>6,7</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Exacerbation of pre-existing diabetes</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Musculoskeletal</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Rhabdomyolysis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Nervous</em></strong><strong><em> System</em></strong></p></td></tr><tr><td><p>Seizures</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Skin and Appendages</em></strong></p></td></tr><tr><td><p>Alopecia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Rash</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong><em>Urogenital</em></strong><strong><em> </em></strong><strong><em>System</em></strong></p></td></tr><tr><td><p>Priapism</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Urinary Incontinence</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Urinary Retention</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td colspan="6"><p><strong><em>Laboratory Analytes</em></strong></p></td></tr><tr><td colspan="6"><p><em>Clinical Chemistry</em></p></td></tr><tr><td><p>Alkaline phosphatase - Increased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr><tr><td><p>Total bilirubin - Increased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>X</p></td></tr></tbody></table><p>1. Adverse event identified from spontaneous post-marketing surveillance.</p><p>e.g., maculopapular rash, anaphylactoid reaction, angioedema, pruritis, or urticaria. i.e., diaphoresis, nausea or vomiting.</p><p>Including a case of thrombocytopenic purpura. COSTART term is diabetic acidosis.</p><p>COSTART term is hyperlipemia.</p><p>Random cholesterol levels of &ge; 6.22 mmol/L and random triglyceride levels of &ge;11.30 mmol/L have been very rarely reported.</p><p>As with other atypical anti-psychotics, there have been isolated post-market reports with olanzapine of serious cardiovascular-related adverse events, including fatalities (see 4.4, Cardiovascular).</p><p>Neutropenia, granulocytopenia and agranulocytosis have been reported during antipsychotic use. Therefore, it is recommended that patients have their complete blood count (CBC) tested prior to starting olanzapine and then <u>periodically </u>throughout treatment.</p><p>Venous Thromboembolism (VTE), including fatal pulmonary embolism, has been reported with antipsychotic drugs, including olanzapine. However, since patients who require treatment with antipsychotics often present with acquired risk factors for VTE all possible risk factors of VTE</p><p>e.g. immobilization, should be identified and preventative measures undertaken.</p><p>Patients should be advised of the risk of severe constipation during olanzapine treatment, and that they should tell their doctor if constipation occurs or worsens, as they may need laxatives.</p><p>&nbsp;</p><p><strong><u>To report any side effect(s)</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and Symptoms</u></p><p>Very common symptoms reported in olanzapine overdose (&ge;10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.</p><p>Other medically significant sequelae of olanzapine overdose include delirium, convulsion, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (&lt;2% of overdose cases) and cardiopulmonary arrest. Fatal outcomes have been reported for acute overdoses as low as 450 mg of oral olanzapine but survival has also been reported following acute overdose of approximately 2,000 mg of oral olanzapine.</p><p>&nbsp;</p><p><u>Management of Overdose</u></p><p>There is no specific antidote for olanzapine. Induction of emesis is not recommended. Standard procedures for management of overdose may be indicated (i.e. gastric lavage, administration of activated charcoal). The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.</p><p>Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function. Do not use epinephrine, dopamine, or other sympathomimetic agents with beta-agonist activity since beta stimulation may worsen hypotension.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>For</strong><strong> </strong><strong>management</strong><strong> of the suspected drug overdose, contact your regional Poison Control Center.</strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olanzapine, a thienobenzodiazepine, is an antipsychotic agent that demonstrates a broad pharmacologic profile across a number of receptor systems. Olanzapine displays high receptor affinity binding <em>in vitro </em>at dopamine D1, D3, D4&nbsp;(Ki = 11-31 nM), 5-HT2A/C&nbsp;(Ki = 4 and 11 nM, respectively), 5-HT3, 5-HT6, muscarinic M1-M5 (Ki = 1.9-2.5 nM), adrenergic &alpha;1&nbsp;(Ki = 19 nM), and histamine H1&nbsp;(Ki = 7 nM) receptor subtypes, while displaying a lower affinity at dopamine D1&nbsp;and D5&nbsp;receptors (Ki = 51 &ndash; 119 nM). &nbsp;In a behavioural paradigm predictive of antipsychotic activity, olanzapine reduced conditioned avoidance response in rats at doses lower than 4 times those required to produce catalepsy. In a single dose (10 mg) PET study in healthy subjects, olanzapine produced higher 5-HT2A than dopamine D2 receptor occupancy. The percent of D2 occupancy was less than the threshold value predictive of extrapyramidal events.</p><p>In animals olanzapine has been observed to produce a significant reduction in the firing of A10 dopaminergic cells. The number of spontaneously active A9 neurons either remained constant or was increased. This may explain the low incidence of extrapyramidal side effects with olanzapine usually associated with the typical antipsychotics.</p><p>Olanzapine also increases extracellular levels of dopamine in a regionally specific manner in the prefrontal cortex, similar to mood stabilizers, lithium and valproate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Oral Administration:</strong></u></p><p><strong>Absorption: </strong>Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours. The absorption is not affected by food.</p><p><strong>Distribution: </strong>Plasma concentrations of orally administered olanzapine were linear and dose proportional in trials studying doses from 1 to 15 mg. The maximum plasma concentrations (Cmax) of olanzapine after single oral doses of 5, 10 and 15 mg averaged 7, 14, and 21 ng/mL, respectively (20 ng/mL = 0.064 &mu;M). In young healthy volunteers, after once-a-day repeated dosing, steady-state Cmax was approximately twice that achieved after a single dose (e.g. 23 ng/mL versus 12 ng/mL for a 10-mg dose). In the elderly, the steady state plasma concentration was approximately 3-fold higher than that achieved after a single dose (e.g. 16 ng/mL versus 5 ng/mL for a 5-mg dose). In both, young and elderly, steady-state concentrations of olanzapine were obtained after seven days of once daily dosing.</p><p>Over time and dosage range, pharmacokinetic parameters within an individual are very consistent. However, plasma concentrations, half-life and clearance of olanzapine may vary between individuals on the basis of smoking status, gender, and age (see Special Populations). Data from pooled, single dose pharmacokinetic studies showed the half-life of olanzapine to range from 21 to 54 hours (5th to 95th percentile), and the apparent plasma clearance to range from 12 to 47 L/hr (5th to 95th percentile).</p><p>The plasma protein binding of olanzapine was about 93% over the concentration range of about &nbsp;7 to about 1000 ng/mL. Olanzapine is bound predominantly to albumin and &alpha;1-acid glycoprotein.</p><p>&nbsp;</p><p><strong>Metabolism: </strong>Olanzapine is metabolized in the liver by conjugative and oxidative pathways. The major circulating metabolite is the 10-N-glucuronide, which is pharmacologically inactive and does not pass the blood brain barrier. Cytochrome P450 isoforms CYP1A2 and CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites. Both metabolites exhibited significantly less <em>in vivo </em>pharmacological activity than olanzapine in animal studies. The predominant pharmacologic activity is from the parent olanzapine.</p><p><em>In vitro </em>microsomal studies show that olanzapine is a weak inhibitor of CYP1A2 (Ki = 36 &mu;M), CYP2D6 (Ki = 89 &mu;M), and CYP3A4 (Ki = 490 &mu;M). Based upon these Ki values, little inhibition of these cytochrome P-450 enzymes is expected <em>in vivo </em>at concentrations below 5 &mu;M (roughly 1500 ng/mL) because the olanzapine concentration will be less than 10% of its Ki value. In clinical studies, observed steady-state plasma concentrations of olanzapine are rarely &gt;150 ng/mL (approximately 0.5 &mu;M). Olanzapine is thus not likely to cause clinically important pharmacokinetic drug-drug interactions mediated through the metabolic routes outlined above. (See 4.5).</p><p>&nbsp;</p><p><strong>Elimination:&nbsp; </strong>After oral administration to healthy subjects, the mean terminal elimination half- life was 33 hours (21 to 54 hours for 5th to 95th&nbsp;percentile) and the mean olanzapine plasma clearance was 26 L/hr (12 to 47 L/hr for the 5th to 95th percentile). Olanzapine pharmacokinetics varied on the basis of smoking status, gender, and age. Table 10 summarizes these effects:</p><p>&nbsp;</p><p><strong>Table 10:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olanzapine Key Pharmacokinetics</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Patient</strong><strong> Characteristics</strong></p></td><td><p><strong>Half-Life (hours)</strong></p></td><td><p><strong>Plasma</strong><strong> Clearance (L/hr)</strong></p></td></tr><tr><td><p>Nonsmoking</p></td><td><p>38.6</p></td><td><p>18.6</p></td></tr><tr><td><p>Smoking</p></td><td><p>30.4</p></td><td><p>27.7</p></td></tr><tr><td><p>Female</p></td><td><p>36.7</p></td><td><p>18.9</p></td></tr><tr><td><p>Male</p></td><td><p>32.3</p></td><td><p>27.3</p></td></tr><tr><td><p>Elderly (65 and older)</p></td><td><p>51.8</p></td><td><p>17.5</p></td></tr><tr><td><p>Nonelderly</p></td><td><p>33.8</p></td><td><p>18.2</p></td></tr></tbody></table><p>Although smoking status, gender, and, to a lesser extent, age may affect olanzapine clearance and half-life, the magnitude of the impact of these single factors is small in comparison to the overall variability between individuals.</p><p>&nbsp;</p><p><strong><u>Special</u></strong><strong><u> Populations and Conditions</u></strong></p><p><strong>Geriatrics:</strong><strong> &nbsp;</strong>In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine was about 1.5 times greater in elderly (&gt;65 years) than in non-elderly subjects (&le; 65 years). Caution should be used in dosing the elderly, especially if there are other factors that might additively influence drug metabolism and/or pharmacodynamic sensitivity (see 4.2).</p><p><strong>Gender: </strong>Clearance of olanzapine is approximately 30% lower in women than in men. There were, however, no apparent differences between men and women in effectiveness or adverse effects. Dosage modifications based on gender should not be needed.</p><p><strong>Race: &nbsp;</strong>In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in olanzapine pharmacokinetics among the three populations. Cytochrome P450 isoform CYP2D6 status does not affect the metabolism of olanzapine.</p><p><strong>Hepatic Insufficiency:&nbsp; </strong>No differences in the single-dose pharmacokinetics of oral olanzapine were noted in subjects with clinically significant cirrhosis (who were mostly smokers) when compared to healthy subjects (all non-smokers). Multiple-dose studies in patients with hepatic impairment, however, have not been performed.</p><p><strong>Renal Insufficiency:&nbsp; </strong>There was no significant difference in mean elimination half-life or olanzapine plasma clearance between subjects with severely impaired renal function compared to individuals with normal renal function. Approximately 57% of radio-labelled olanzapine is excreted in urine, principally as metabolites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An extensive series of acute, subchronic, chronic, reproduction, and genetic toxicity as well as oncogenicity studies have been conducted to support clinical trials with olanzapine. In most of these studies, olanzapine was given by the oral route to rodents, rabbits, and monkeys in an aqueous suspension with 5% to 10% acacia and to dogs as neat material in capsules.</p><p>The predominant effects in laboratory animals given olanzapine were CNS depression and anticholinergic effects related to the pharmacology of the drug. Tolerance to the CNS depression developed in repeated-dose studies. Depressed body weight gain was a consistent finding in mice given 30 mg/kg/day and in rats given 4 mg/kg/day. Effects on hematology parameters were found in each species studied in repeated-dose studies. Rats given 16 mg/kg/day had decreased lymphocyte and neutrophil counts and atrophy of bone marrow consistent with the marked reduction in body weight gain. Mice given 3 mg/kg/day developed leukopenia, due primarily to lymphocytopenia, but also associated with neutropenia. Lymphoid necrosis of thymus and spleen was seen in mice given &ge; 10 mg/kg/day. Instances of reversible neutropenia, with or without thrombocytopenia, or anemia developed in a low number of individual dogs treated with 8 or 10 mg/kg/day. Bone marrow from some dogs with olanzapine-induced neutropenia responded to olanzapine with lower than expected numbers of maturing granulocytic cells; however, progenitor and proliferating cells were present in adequate numbers. No olanzapine-related hematologic effects were seen in dogs receiving olanzapine at either 2 or 5 mg/kg/day.</p><p>Effects observed in rats consistent with increased plasma concentrations of prolactin in rats included decreased weights of ovaries and uterus. Histopathologic tissue alterations in mammary gland morphology and vaginal epithelium and increased prominence of ovarian follicles were also consistent with elevated prolactin concentrations. Prolactin-induced histopathologic tissue alterations found in rats regressed after treatment cessation. No unexpected toxicologically important findings unrelated to pharmacologic activity were found in the 1-year studies in rats given 4 mg/kg/day or in dogs given 5 mg/kg/day.</p><p>In a rat oncogenicity study, the only neoplasm with increased incidence related to treatment was malignant mammary gland tumours in females of the 4- and 8-mg/kg/day groups (initial dose levels were increased from 2.5 and 4 mg/kg/day, respectively, on Day 211). The overall incidence of mammary gland tumours was not increased. The shift in expression of mammary gland tumours was not unexpected and was consistent with effects due to elevated prolactin concentrations in rodents. Also consistent with increased prolactin concentrations was an increased total incidence of mammary gland tumours in female mice given 10 or 20 mg/kg/day (the high dose was decreased from 30 mg/kg/day due to excess mortality).</p><p>Olanzapine had no mutagenic or teratogenic effects. Mating performance was affected in male rats given 5 mg/kg/day, but the effect was quickly reversed when treatment stopped. Estrous cycles were affected and reproduction parameters were influenced in rats given the higher doses of &ge; 1 mg/kg/day. No adverse effects were observed on numbers of corpora lutea, implantations, fetal viability, or fetal weight, and there were no effects on litter size or on the survival, growth, or development of the offspring from parents given up to 5 mg/kg/day. Transient modest decreases in activity levels of the progeny from females given 0.25 mg/kg/day and skeletal changes indicative of growth retardation in fetuses from females given 5 mg/kg/day were observed. Although the reproductive process in female rats from mating through fertilization was not adversely affected by treatment, this evidence does not exclude a possible interference with maintenance of pregnancy at high doses of olanzapine.</p><p>The findings of toxicology studies support the safety of olanzapine for oral use in humans as an antipsychotic agent.</p><p>&nbsp;</p><p><strong><u>Acute Toxicity Studies:</u></strong></p><p>The acute toxicity of olanzapine was studied in mice, rats, dogs, and monkeys. The estimated median lethal dose for each species is shown below in Table 14:</p><p>&nbsp;</p><p><strong>Table 14: Acute Toxicity Summary</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;Species</strong></p></td><td rowspan="2"><p><strong>&nbsp;Route</strong></p></td><td colspan="2"><p><strong>Estimated</strong><strong> Median Lethal Dose (mg/kg/day)</strong></p></td></tr><tr><td><p><strong>Males</strong></p></td><td><p><strong>Females</strong></p></td></tr><tr><td><p>Mouse</p><p>Rat</p><p>Dog</p><p>Monkey</p><p>Rat</p></td><td><p>Oral</p><p>Oral</p><p>Oral</p><p>Nasogastric</p><p>Intraperitoneal</p></td><td colspan="2"><p>211&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 208</p><p>174&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 177</p><p>Both sexes &gt;100 mg/kg</p><p>Both sexes &gt;100 mg/kg</p><p>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 107</p></td></tr></tbody></table><p>Signs of toxicity in rodents included hypoactivity, lethargy, leg weakness, coma, tremors, clonic convulsions, salivation, poor grooming, and depressed body weight gain.</p><p>The potential for irritation of an aqueous intramuscular formulation of olanzapine was tested in one <em>in vitro </em>and two <em>in vivo </em>(dog and rabbit) studies. The intent of these studies was to characterize the effects at the site of injection. Overall, these tests indicated that formulations of olanzapine, at 1.7 to 8.4 mg/mL in a tartaric acid/lactose vehicle, have the potential to cause slight irritation of skeletal muscle. While the <em>in vitro </em>model suggested a potential for moderate irritation at the higher concentrations tested, the <em>in vivo </em>models indicated either very little or slight potential for irritation.</p><p>&nbsp;</p><p><u>Subchronic/Chronic/Carcinogenicity and Related Toxicity Studies:</u></p><p><em>Subchronic Toxicity</em><em> Studies:</em></p><p>Subchronic administration studies of up to 3 months in duration have been conducted by the oral route in mice, rats, and dogs.</p><p>&nbsp;</p><p><em>Chronic Toxicity Studies:</em></p><p>Chronic administration studies of up to 1 year were conducted by the oral route in rats and dogs.</p><p>&nbsp;</p><p><em>Carcinogenicity Studies:</em></p><p>The oncogenic potential of olanzapine was evaluated in studies in rats and mice. Carcinogenicity studies were conducted in CD-1 mice and Fischer 344 rats. Olanzapine was administered orally to mice at doses of 3, 10, or 20 mg/kg for 19 months (males) or 21 months (females) in an initial study, and in a subsequent study at doses of 0.5, 2, or 8 mg/kg for 21 months (males and females). Rats received oral doses of 0.25, 1, 2.5, or 4 mg/kg (males) or 0.25, 1, 2.5, 4, or 8 mg/kg (females) for 24 months. These doses are equivalent to 2 to 70 times the maximum daily human dose (mouse studies) or 0.9 to 28 times the maximum daily human dose (rats). A maximum tolerated dose was achieved in both mouse and rat studies. Increased mortality was seen in mice at doses of 10 and 20 mg/kg and decreases in circulating lymphocytes and neutrophils were seen at doses 0.5 mg/kg. In female mice treated with olanzapine, the incidence of mammary tumours was increased at doses 2 mg/kg. Female rats treated with 4 or 8 mg/kg had an increase in malignant mammary tumours, but the overall incidence of mammary gland neoplasia was unchanged. Antipsychotic drugs, including olanzapine, have been shown to chronically elevate prolactin concentrations in rodents. An increase in mammary neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be prolactin mediated. The role of prolactin in human breast cancer has <em>not </em>been defined conclusively, and there are presently no epidemiologic data indicating increased risk for breast cancer for humans using antipsychotic drugs.</p><p>&nbsp;</p><p><u>Reproduction Studies:</u></p><p>Fertility studies in male and female rats and teratology studies in rats and rabbits have been conducted by the oral route. Mating performance was affected by administration of olanzapine due to sedation in male rats given doses greater than 18 times the maximum daily human dose, but the effect was quickly reversed when treatment stopped. Estrous cycles were affected and reproduction parameters were influenced in rats given doses greater than 4 times the maximum daily human dose. No adverse effects were observed on numbers of corpora lutea, implantations, fetal viability, or fetal weight, and there were no effects on litter size or on the survival, growth, or development of the offspring from parents given up to 18 times the maximum daily human dose. Although the reproductive process in female rats from mating through fertilization was not adversely affected by treatment, this evidence does not exclude a possible interference with maintenance of pregnancy at high doses of olanzapine. Reproduction studies, performed in rats and rabbits at doses of olanzapine <em>3.5 </em>and 7 times the maximum daily human dose (20 mg), respectively, have revealed no evidence of harm to the fetus. Maternal toxicity, developmental toxicity (indicated by fetal growth retardation and slightly delayed ossification at birth), and increased numbers of nonviable offspring occurred at higher doses (in rats at 14 and 63 times the maximum daily human dose and in rabbits at 28 and 105 times the maximum daily human dose). However, fetal malformations were not increased. Transient decreases in offspring activity have occurred at all doses; however, there were no effects on body weight, growth, mating, fertility, or live births in second-generation animals. Placental transfer of olanzapine occurs in rat fetuses.</p><p>Olanzapine was also detected in the milk of rats at concentrations up to three-fold higher than those in the plasma.</p><p>&nbsp;</p><p><u>Mutagenicity Studies:</u></p><p>Olanzapine was not mutagenic or clastogenic in a full range of standard tests which included bacterial mutation tests and <em>in vitro </em>and <em>in vivo </em>mammalian tests. Appropriate positive controls were used in each test to verify the sensitivity of the test systems.</p><p>&nbsp;</p><p><u>Hematologic Indices:</u></p><p>In animal studies with olanzapine, the principal hematologic findings were reversible peripheral cytopenias in individual dogs given high doses of olanzapine (24 to 30 times the maximum daily human dose), dose-related decreases in lymphocytes and neutrophils in mice, and lymphopenia secondary to compromised nutritional status in rats. A few dogs treated with 24 to 30 times the maximum daily human dose developed reversible neutropenia or reversible hemolytic anemia between 1 and 10 months of treatment. Effects on hematology parameters in each species involved circulating blood cells, and no evidence of bone marrow cytotoxicity was found in any of the species examined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3"><p><strong>&nbsp;INGREDIENTS</strong></p></td><td rowspan="3"><p><strong>FUNCTION</strong></p></td><td colspan="3"><p><strong>QUANTITY</strong></p></td></tr><tr><td rowspan="2"><p><strong>% w/w</strong></p></td><td colspan="2"><p><strong>mg/tab</strong></p></td></tr><tr><td><p><strong>5mg</strong></p></td><td><p><strong>10mg</strong></p></td></tr><tr><td colspan="2"><p><strong>CORE</strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Olanzapine USP</p></td><td><p>Active</p></td><td><p>2.213</p></td><td><p>5.00</p></td><td><p>10.0</p></td></tr><tr><td><p>Lactose Monohydrate NF (Spray dried)</p></td><td><p>Diluent</p></td><td><p>58.85</p></td><td><p>133.0</p></td><td><p>266.0</p></td></tr><tr><td><p>Magnesium stearate NF</p></td><td><p>Lubricant</p></td><td><p>26.55</p></td><td><p>60.0</p></td><td><p>120.0</p></td></tr><tr><td><p>Microcrystalline cellulose NF (PH 102)</p></td><td><p>Binder and diluent</p></td><td><p>0.708</p></td><td><p>1..60</p></td><td><p>3.20</p></td></tr><tr><td><p>Cornstarch NF</p></td><td><p>Disintegrant</p></td><td><p>9.027</p></td><td><p>20.40</p></td><td><p>40.8</p></td></tr><tr><td colspan="2"><p><strong>Total Core Tablet weight</strong></p></td><td><p><strong>97.35</strong></p></td><td><p><strong>220.0</strong></p></td><td><p><strong>440.0</strong></p></td></tr><tr><td colspan="2"><p><strong>Film Coating</strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910 USP</p></td><td><p>Film forming polymer</p></td><td><p><strong>&nbsp;</strong></p><p>0.796</p></td><td><p><strong>&nbsp;</strong></p><p>1.80</p></td><td><p><strong>&nbsp;</strong></p><p>3.60</p></td></tr><tr><td><p>Hydroxypropyl Cellulose NF Type LF</p></td><td><p>Film forming polymer</p></td><td><p>0.265</p></td><td><p>0.60</p></td><td><p>1.20</p></td></tr><tr><td><p>Polyethylene Glycol NF 8000</p></td><td><p>Plasticizer</p></td><td><p>0.531</p></td><td><p>1.20</p></td><td><p>2.40</p></td></tr><tr><td><p>Titanium Dioxide USP</p></td><td><p>Colorant</p></td><td><p>1.062</p></td><td><p>2.40</p></td><td><p>4.80</p></td></tr><tr><td><p>Purified Water$ USP</p></td><td><p>Solvent</p></td><td><p>--</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td colspan="2"><p><strong>Total Film-coating solution (excluding water)</strong></p></td><td><p><strong>2.65</strong></p></td><td><p><strong>6.0</strong></p></td><td><p><strong>12.0</strong></p></td></tr><tr><td colspan="2"><p><strong>Total Tablet weight (Excluding water)</strong></p></td><td><p><strong>100</strong></p></td><td><p><strong>226.0</strong></p></td><td><p><strong>452.0</strong></p></td></tr></tbody></table><p>$ Does not contribute to the weight of the coated tablets. Evaporates during drying process</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. &nbsp;Protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Packaging:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Unit</strong><strong> </strong><strong>Count</strong><strong> </strong><strong>or</strong><strong> </strong><strong>Fill Size</strong></p></td><td><p><strong>Strength</strong></p></td><td><p><strong>Pack</strong><strong> </strong><strong>Type</strong></p></td><td><p><strong>Description</strong></p></td></tr><tr><td><p>28&rsquo;s</p></td><td><p>5mg and 10mg</p></td><td><p>Blister</p></td><td><p>Film: Cold formable foil 205MM</p><p>Foil: Foil silver plain 205MM 25 &micro;M.</p></td></tr></tbody></table><p>Secondary Packaging: Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated 150 Signet Drive Toronto, Ontario Canada, M9L 1T9
Tel: 1-800-268-4623, Fax: 1-800-609-9444
www.apotex.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>